



**Vaccines and Global Health: The Week in Review**  
**4 December 2021 :: Issue 635**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents**

:: [Milestones - Perspectives](#)

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

## ***Milestones - Perspectives***

.....  
.....

### **Gavi Board approves malaria vaccine programme funding, COVAX 2022 strategic approach and measures to maintain, restore and strengthen routine immunisation**

- A new malaria vaccination programme has been approved, providing Gavi-eligible countries in sub-Saharan Africa a powerful new tool with which to fight malaria
- In 2022, Gavi, through COVAX, will continue to help countries meet COVID-19 vaccination targets, focusing mostly on lower-income countries and those most in need including support for delivery at scale
- Gavi will invest US\$ 250 million over 2022-2026 in its partnership with India; US\$ 53 million over 2022-2025 will be channelled towards supporting the availability of diagnostic tests for yellow fever, cholera, typhoid, meningococcus, measles, and rubella
- José Manuel Barroso, Board Chair: "I am greatly heartened that the Gavi Board has endorsed decisions that allow progress to be made on all fronts: for leveraging the latest innovations to tackle malaria, for COVAX to support national COVID-19 vaccination strategies, and for maintaining, restoring and strengthening routine immunisation programmes – including targeting the increasing numbers of zero dose children in the world today."

Geneva, 3 December 2021 – **The Board of Gavi, the Vaccine Alliance this week approved a number of measures aimed at tackling malaria, driving equitable global access to COVID-19 vaccines and maintaining, restoring and strengthening routine immunisation in 2022.**

During the three-day meeting, the Board approved a new malaria vaccination programme to support the introduction, procurement and delivery of the malaria vaccine to Gavi-eligible countries in sub-Saharan Africa. An initial investment of US\$ 155.7 million for 2022-2025 will initiate the implementation of this additional tool in the fight against malaria alongside currently recommended malaria control interventions, which could save tens of thousands of lives annually and drive down child mortality in Africa.

The Board also approved the Vaccine Alliance's strategic direction and role in COVAX. In 2022, Gavi, through COVAX, will continue building the foundations of COVID-19 protection with a focus on lower-income countries and the most in need; deploying a flexible portfolio of COVID-19 vaccines to manage uncertainty and anticipate risk; and providing support for delivery at-scale.

**"Events of 2021, illustrated most recently by the emergence of the omicron variant, have highlighted the danger of leaving COVID-19 to flourish unchecked in large parts of the world, but also of the vital importance of maintaining routine life-saving immunisation programmes that have been hit so hard by the pandemic", said José Manuel Barroso, Chair of the Gavi Board.** "I am greatly heartened that the Gavi Board has endorsed decisions that allow progress to be made on all fronts: for leveraging the latest innovations to tackle malaria, for COVAX to support national COVID-19 vaccination strategies, **and for maintaining, restoring and strengthening routine immunisation programmes – including targeting the increasing numbers of zero dose children in the world today.**"

## ***Malaria vaccine programme***

**The Board's historical approval of a malaria vaccine programme and financing will provide a critical new tool for African countries in the fight against malaria. With an initial investment of approximately US\$ 155.7 million for 2022-2025,** the Board noted that a successful malaria vaccine programme should support deliberate and intensive coordination between malaria control and immunisation programmes at global and country levels to ensure most impactful deployment of the vaccine alongside other interventions.

The Board also recognised the opportunity for integration and strengthening of primary healthcare given the wide acceptance of the vaccine among caregivers and healthcare workers, as was seen during the Malaria Vaccine Implementation Programme (MVIP). Child immunisation provides a powerful platform to reach vulnerable children, including those who are unreached with bednets or other existing prevention measures, and can help advance the equity agenda. Finally, the Board noted opportunities for next generation vaccines and a need for market-shaping efforts to support the development of a healthy malaria vaccine market.

"Today marks an important milestone in our fight against malaria," said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. **"This decision by the Gavi Board to finance a new malaria vaccination programme for countries in sub-Saharan Africa could save tens of thousands of lives annually in Africa. The vaccine is an important additional tool to control malaria in Africa, alongside other interventions,** such as routine use of insecticide-treated bed nets, indoor spraying with insecticides, malaria chemoprevention, and timely testing and treatment. We look forward to working with global malaria stakeholders to make sure that countries are able to implement this additional tool in the fight against malaria."

**After considerable gains in the past two decades, progress in malaria control has stalled** and new tools are urgently needed to get back on track. More than 260,000 African children under the age of five die from malaria annually, and six Gavi-eligible countries account for 50% of global mortality. Africa continues to bear the heaviest malaria burden and African children are at highest risk of dying of malaria, especially at a time when the COVID-19 pandemic threatens disruptions to immunisation programmes.

Following the decision by the Gavi Board, a series of critical next steps will need to take place before the vaccine is rolled-out to Gavi-supported countries. This includes technical guidance on the use of the vaccine alongside other malaria interventions, procurement of the vaccine, and the opening of the funding window to allow applications from Gavi-supported countries. Additionally, countries will need to make decisions on the rollout of malaria vaccine, taking in consideration such factors as the public health priority of the disease, evidence of disease burden, and the optimal mix of malaria interventions tailored to the local context.

### ***COVAX's 2022 strategic approach***

The Board approved the Vaccine Alliance's **strategic direction for 2022 to support 91 lower-income countries** towards achieving their individual COVID-19 vaccination coverage ambitions in view of the WHO Global Vaccination Target of 70% by mid-2022 and taking into account sources of supply beyond COVAX. COVAX has supplied over 80% of all vaccines shipped to low-income countries and has secured access to enough additional doses to protect around 40% of each countries' population by early next year.

Subject to funding availability for the COVAX AMC, the COVAX Facility's approach to procurement of COVID-19 vaccines for 2022, devised to provide maximum flexibility in the event of new evidence appearing or markets evolving, was also approved by the Gavi Board. **The core element of the approach, the Pandemic Vaccine Pool,** will enable COVAX to manage demand- and supply-side risks, as well as provide doses to the countries that are most reliant on COVAX, including vulnerable countries, countries where current rates of coverage are the lowest and others that need certainty of supply in order to be able to plan successfully.

The COVAX 2022 strategic approach also recognises the difference in countries' capacity to roll-out vaccines and the fact that many partners are providing support to countries to scale up delivery. The Alliance's role in the scale up of COVID-19 vaccination in 2022 will focus on more systematic collaboration with other funders at global, regional and country levels; more targeted financial support and enhanced technical support to AMC-eligible countries; as well as enhanced monitoring of delivery progress and risks.

**In order to strengthen COVAX's processes from supply allocation to last mile delivery, the Board recognised the need to establish an enhanced and unified COVAX delivery coordination structure,** agreeing to set up a temporary Steering Committee with delegated authority over delivery-related strategy and decisions of the COVAX Facility. The Committee will also oversee COVID-19 vaccination delivery support provided by COVAX, including alignment on allocation strategy, country absorptive capacity and funding. Recognising the important role that each Vaccine Alliance member needs to play in this coordination structure, it also requested that the new structure work with existing and additional partners and countries to rapidly accelerate vaccination delivery, including through campaigns, mass vaccination and hard-to-reach populations while safeguarding routine immunisation. The enhanced coordination structure will report on delivery progress to the Gavi Board through the temporary Steering Committee on a regular basis.

**The Board also delegated to Gavi, at the guidance of the new COVAX coordination structure, the authority to allot current and future COVID-19 delivery funding without requiring independent review given the emergency context and urgent country needs, while utilising existing programmatic and fiduciary risk mitigation mechanisms.**

The Board also noted the importance of COVAX's cost-sharing mechanism as an important voluntary mechanism for countries to access additional doses and approved its extension until December 2023.

### ***Disease surveillance and diagnostics***

**As part of Gavi's efforts to restore, maintain and strengthen routine immunisation, the Board approved US\$ 32 million in funding in 2022-2025 for costs related to the procurement and distribution of yellow fever, cholera, typhoid, meningococcus, measles, and rubella diagnostic test kits, reagents, supplies, and equipment.** This market purchase commitment will put incentives in place for improved commercially available diagnostics. Additionally, US\$ 21 million was approved to ensure that any test kits procured with Gavi funding are accurate, reliable, and useful for vaccine programmes' efforts to use vaccines in the right places and times.

Fit-for-purpose diagnostic tools are critical for countries' abilities to plan and implement targeted vaccination programmes. Making such diagnostic tools available to countries will help make sure that Gavi investments in these vaccine programmes, which are currently projected at over US\$ 1.6 billion during 2021-2025, will be more efficient, effective, and equitable.

***The Board also approved:***

- **The renewed Gavi's strategic partnership with India and the associated investment of US\$ 250 million for 2022-2026, which will aim to further decrease the number of zero-dose and under-immunised children** and expand full immunisation coverage in the next five years, as well as provide catalytic support for the introduction of Human papillomavirus (HPV) and Typhoid conjugate vaccines (TCV) in India.
- The Gavi's private sector engagement strategy which is expected to play a critical role in supporting the strategic priorities of Gavi 5.0 and COVAX related objectives, such as the zero-dose agenda, Covid vaccine delivery, innovation from the private sector and immunisation systems strengthening.
- The Risk & Assurance Report 2021, which shows that **Gavi's overall risk profile remains elevated due to the ongoing uncertain environment**, Gavi's ambitious strategy and the unprecedented mission of the COVAX Facility. As per Gavi's updated Risk Appetite Statement, approved by the Board in its June 2021 meeting, these risks are worth taking, but Gavi continues to actively monitor and mitigate them to the extent possible.
- The Financial Forecast for Gavi 5.0 for the 2021-2025 strategic period and the Financial Forecast for Gavi COVAX AMC for the 2020-2022 period.

Finally, the Gavi Board gave a warm send-off to Maty Dia, Abdoulaye Sabre Fadoul, Gilbert Mokoki, David Sidwell and Joan Valadou, who have all made an important contribution to Gavi's efforts to accelerate the introduction of new vaccines and improve routine immunisation. **The Board also welcomed new members**, including Bernhard Braune, Silvia Lutcuta, Bvudzai Magadrize, Charlemagne Marie Ragnag-Néwendé Ouedraogo, Jan Paehler, **Anne Schuchat** and Rafael Vilasanjuan.

.....  
.....

**WHO Pandemic Ethics & Policy Summit**

6 December 2021

*Equitable access, solidarity, and global health justice: Bridging the gap between ethics and decision-making in pandemics*

From resource allocation and priority-setting, access to vaccines, vaccine mandates, lockdowns, travel restrictions, public health surveillance, and obligations to conduct clinical trials, the COVID-19 pandemic has raised profound ethical challenges on an unprecedented global scale.

At the same time, and also in an unprecedented manner, ethical values like equity, fairness, solidarity, and trust have figured prominently in global political discussions. Despite an abundance of guidance, the question remains: how much progress, if any, have we made in achieving these values, in advancing towards global health justice? Much has been said about the importance of evidence-informed decision-making, but what have we achieved in terms of 'Ethics-informed decision-making'? This Summit provides a forum to discuss the translation of ethics into policy making in COVID-19; where we have succeeded and failed; what are the major challenges and what steps need to be taken to improve ethics informed public health decision-making for pandemic preparedness and response.

The Summit is organized by the WHO Health Ethics and Governance Unit in collaboration with the WHO's Working Group on Ethics & COVID-19 and the ACT-Accelerator Ethics & Governance Working Group.

Confirmed speakers include: Thalia Arawi, Caesar Atuire, Alena Buyx, Ezekiel Emanuel, Ruth Faden, Anthony Fauci, Christine Grady, Fatima Hassan, Sharon Kaur, Ilona Kickbusch, Florencia Luna, Roli Mathur, Peter Singer, Jerome Singh, Soumya Swaminathan, Beatriz Thomé, Ross Upshur, Effy Vayena.

**Register Here:** [https://who.zoom.us/webinar/register/WN\\_hjp0eY19RDawdZfj1EML8Q](https://who.zoom.us/webinar/register/WN_hjp0eY19RDawdZfj1EML8Q)

.....

### **Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 7 December 2021**

7 December 2021

This extraordinary virtual meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will take place on Tuesday 7 December 2021 to propose recommendations to WHO on the use of COVID-19 vaccine(s).

Agenda: [https://cdn.who.int/media/docs/default-source/immunization/sage/2021/december/sage-agenda-7dect2021-virtual-draft-rev26nov.pdf?sfvrsn=f2b71e9f\\_10](https://cdn.who.int/media/docs/default-source/immunization/sage/2021/december/sage-agenda-7dect2021-virtual-draft-rev26nov.pdf?sfvrsn=f2b71e9f_10)

.....

.....

### **World Health Assembly - Special Session**

#### **WHASS2: Special session of the World Health Assembly referred to in decision WHA74(16)**

29 November – 1 December 2021

Geneva, Switzerland | Virtual event

#### **WHASS2 Documents** [at 4 Dec 2021]

:: Statements submitted by Member States and other participants at the Second special session of the World Health Assembly.

:: Statements by non-State actors in official relations with WHO at the WHO governing bodies meetings

#### **Decisions**

#### **The World Together: Establishment of an intergovernmental negotiating body to strengthen pandemic prevention, preparedness and response**

SSA2(5) 1 December 2021 :: 2 pages

The Second special session of the World Health Assembly,

:: Recalling resolution WHA74.7 and decision WHA74(16), and welcoming the report of the Member States Working Group on Strengthening WHO Preparedness and Response to Health Emergencies (WGPR),<sup>1</sup>

:: Expressing appreciation for the ongoing work of the WGPR under resolution WHA 74.7, including to identify the tools to implement the recommendations that fall under the technical work of WHO and further develop proposals to strengthen the International Health Regulations (IHR (2005)) including potential targeted IHR (2005) amendments, and elements that may most effectively be addressed in other venues;

:: Acknowledging the need to address gaps in preventing, preparing for, and responding to health emergencies, including in development and distribution of, and unhindered, timely and equitable

access to, medical countermeasures such as vaccines, therapeutics and diagnostics, as well as strengthening health systems and their resilience with a view to achieving UHC;

:: Emphasizing the need for a comprehensive and coherent approach to strengthen the global health architecture, and recognizing the commitment of Member States to develop a new instrument for pandemic prevention, preparedness and response with a whole-of-government and whole-of-society approach, prioritizing the need for equity;

:: Stressing that Member States should guide their efforts to develop such an instrument by the principle of solidarity with all people and countries, that should frame practical actions to deal with both causes and consequences of pandemics and other health emergencies.

## **1. DECIDES:**

**(1) to establish, in accordance with Rule 41 of its Rules of Procedure, an intergovernmental negotiating body open to all Member States and Associate Members<sup>2</sup> (the "INB") to draft and negotiate** a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response, with a view to adoption under Article 19, or under other provisions of the WHO Constitution as may be deemed appropriate by the INB;

**(2) that the first meeting of the INB shall be held no later than 1 March 2022**, in order to elect two co-chairs, reflecting a balance of developed and developing countries, and four vice-chairs, one from each of the six WHO regions, and to define and agree on its working methods and timelines, consistent with this decision and based on the principles of inclusiveness, transparency, efficiency, Member State leadership and consensus;

(3) that as part of its working methods, the INB shall determine an inclusive Member State led process, to be facilitated by the co-chairs and vice-chairs, to first identify the substantive elements of the instrument and to then begin the development of a working draft to be presented, on the basis of progress achieved, for the consideration of the INB at its second meeting, to be held no later than 1 August 2022, at the end of which the INB will identify the provision of the WHO Constitution under which the instrument should be adopted in line with paragraph 1(1);

(4) that the process referred to in paragraph 1(3) should be informed by evidence and **should take into account the discussions and outcomes of the Member States Working Group on Strengthening WHO Preparedness and Response to Health Emergencies**, considering the need for coherence and complementarity between the process of developing the new instrument and the ongoing work under resolution WHA74.7, particularly with regard to implementation and strengthening of the IHR (2005);

**(5) that the INB shall submit its outcome for consideration by the Seventy-seventh World Health Assembly [2024]**, with a progress report to the Seventy-sixth World Health Assembly;

## **2. REQUESTS the Director-General to support the INB by:**

(1) convening its first meeting no later than 1 March 2022, and subsequent meetings at the request of the co-chairs as frequently as necessary;

(2) holding public hearings, in line with standard WHO practice, prior to the second meeting of the INB to inform its deliberations;



(3) facilitating the participation, to the extent the INB so decides, in accordance with relevant Rules of Procedure and resolutions and decisions of the Health Assembly, of representatives of organizations of the United Nations system and other intergovernmental organizations with which WHO has established effective relations, Observers, representatives of non-State actors in official relations with WHO, and of other relevant stakeholders and experts as decided by the INB, recognizing the importance of broad engagement to ensure a successful outcome;

(4) providing the INB with the necessary services and facilities for the performance of its work, including complete, relevant and timely information and advice.

*Fifth plenary meeting, 1 December 2021 SSA2/SR/5*

.....

### **WHO Director-General's closing remarks at the Special Session of the World Health Assembly -**

*Speech*

01 December 2021

*[Excerpts]*

...I thank you for the overwhelming support expressed by Member States for the need for a new accord on pandemic preparedness and response.

**I welcome the decision you have adopted today, to establish an intergovernmental negotiating body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response**, with a view to adoption under Article 19, or under other provisions of the WHO Constitution as may be deemed appropriate by the intergovernmental negotiating body.

I welcome your commitment to an inclusive, transparent and efficient process, led by Member States and based on consensus.

**I welcome your commitment to hold the first meeting of the INB no later than the first of March 2022, and to submit its outcome for consideration to the World Health Assembly in 2024.**

And I give you my commitment that the Secretariat will support this process...

I call on all Member States to choose to achieve our targets of vaccinating 40% of the population of every country by the end of this year, and 70% by the middle of next year.

I call on those countries that have already reached 70% to choose to swap your vaccine delivery schedules with COVAX and AVAT, as Switzerland has just done;

I call on all Member States to choose to remove every barrier to scaling up vaccine production, by sharing technology and know-how, and by supporting a waiver of intellectual property rights.

I call on those countries that have promised to donate vaccines to choose to make good on those promises, as urgently as possible.

I call on Member States to choose to fully fund the ACT Accelerator, which needs 23.4 billion U.S. dollars over the next 12 months to get tests, treatments and vaccines to where they are needed most.

I call on every Member State to choose a comprehensive, tailored, layered combination of proven public health and social measures to reduce transmission, reduce the pressure on your health systems, and save lives.

I call on all Member States to focus on strengthening and optimizing clinical pathways, from primary to intensive care, ensuring the right patient get the right care at the right time, and that health workers are supported and protected while doing their life-saving work.



I call on all Member States to intensify and target risk communication, strengthen community engagement, empowerment and support, addressing community concerns, combatting misinformation and building trust.

I call on every Member State to choose to increase surveillance, testing, sequencing and reporting, and to refrain from penalizing countries that do, in compliance with the International Health Regulations.

And I call on all Member States to choose to commit to strengthening your WHO, especially by supporting the proposals of the Working Group on Sustainable Financing.

We are one humanity. We have one planet. We have one health. And we have one WHO. Your WHO.

*1 Document SSA2/3.*

*2 And regional economic integration organizations as appropriate.*

.....  
.....

## **WTO - TRIPS Waiver Status**

### **DG calls on members to agree on pandemic response, fisheries subsidies by end-February**

2 December 2021

Following last week's eleventh-hour decision by WTO members to postpone the 12th Ministerial Conference, negotiations are continuing in Geneva, and **Director-General Ngozi Okonjo-Iweala today (2 December) urged delegation heads to redouble their efforts to bridge differences. She called on them to conclude agreements on the WTO system's response to pandemics** as well as on curbing harmful fisheries subsidies by the end of February 2022 to pave the way for approval by ministers. **"Seven billion people are waiting for us on TRIPS and pandemic response.** And 260 million people are waiting for us on fisheries subsidies," she said.

Speaking to a meeting of delegation heads from all WTO members, the Director-General said the decision to postpone MC12 was "as disappointing as it was necessary". In addition to the potential health risks from the Omicron variant, travel restrictions introduced in response to its emergence had made it impossible for all ministers to participate on an equitable basis at the conference, which had been set to run from 30 November to 3 December in Geneva.

Just because the ministerial had been postponed did not mean that negotiations had stopped, the Director-General emphasised. She welcomed the ongoing meetings among ambassadors and experts to try to keep bridging gaps they had narrowed over the course of weeks of nearly round-the-clock preparatory negotiations and encouraged them to continue. The challenge for them now was to "recover from last week's unexpected setback to deliver results for the people we serve".

DG Okonjo-Iweala said she had spoken to several ministers in recent days, and they all wanted negotiations in Geneva to continue — and to deliver results.

She pointed to a joint letter that the officers of MC12 — Conference Chair Timur Suleimenov, President's Envoy for International Trade of Kazakhstan, and Vice-Chairs Dan Tehan, Minister for Trade, Tourism and Investment of Australia; Jerome Xavier Walcott, Minister for Foreign Affairs and Foreign Trade of Barbados; and Harriet Ntabazi, Minister of State for Trade of Uganda — had sent to ministers from all WTO members, asking them to empower Geneva representatives to resolve outstanding differences so that ministers can reconvene in March to adopt agreements. That letter

called for prioritizing outcomes on pandemic response, including a “sensible solution” on the proposed intellectual property waiver, given the global health situation, as well as on fisheries subsidies, where recent convergence had put a deal in the long-running negotiations within reach.

“If we were ready to make progress this week, we can finish pandemic response and fisheries subsidies by the end of February, and know where we are on agriculture,” the Director-General said.

**“The pandemic is raging — people are dying globally in numbers similar to April 2020. The public expects a response from WTO members,” she added. “The new Omicron variant has reminded us once again of the urgency of achieving equitable access to vaccines in every country in the world.”**

“It underscores how important it is for us to converge on the WTO's contribution to achieving this goal, **including the TRIPS dimension. I strongly believe that a comprehensive response to the pandemic must include intellectual property,**” she said, urging all sides to come together to find a compromise.

Noting that it was not clear whether the epidemiological situation would permit ministers to gather in March, the Director-General said Geneva representatives should seek to prepare clean texts, or at most texts with one outstanding issue to be resolved, for ministers. This would permit them to finalize or bless an outcome even if they have to do so remotely.

**“Let us aim to finish pandemic response and fisheries by end February. And let us agree that ministers should be able to finalise them without physical presence. Seven billion people are waiting for us on TRIPS and pandemic response. And 260 million people are waiting for us on fisheries subsidies,”** she said.

She urged delegations to advance where possible in the days remaining before the WTO's winter break and to return early in January with “guidance and instructions for getting us to the finish line”.

.....  
.....

### **Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries**

*A joint statement from the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention (Africa CDC) and COVAX*

29 November 2021| Addis Ababa| Geneva.

Building on lessons learned from our collective experience with dose donations over the past several months, the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention (Africa CDC) and COVAX wish to draw the attention of the international community to the situation of donations of COVID-19 vaccines to Africa, and other COVAX participating economies, particularly those supported by the Gavi COVAX Advance Market Commitment (AMC).

AVAT and COVAX complement each other's efforts to support African countries to meet their immunisation targets, recognising the global goal of immunising 70% of the African population. Dose donations have been an important source of supply while other sources are stepping up, but the quality of donations needs to improve.

AVAT and COVAX are focused on accelerating access to and rollout of COVID-19 vaccines in Africa. Together we are rapidly expanding supply to the continent, and providing countries with the support to be able to utilise the doses they receive. To date, over 90 million donated doses have been delivered to the continent via COVAX and AVAT and millions more via bilateral arrangements.

**However, the majority of the donations to-date have been ad hoc, provided with little notice and short shelf lives. This has made it extremely challenging for countries to plan vaccination campaigns and increase absorptive capacity. To achieve higher coverage rates across the continent, and for donations to be a sustainable source of supply that can complement supply from AVAT and COVAX purchase agreements, this trend must change.**

**Countries need predictable and reliable supply. Having to plan at short notice and ensure uptake of doses with short shelf lives exponentially magnifies the logistical burden on health systems that are already stretched. Furthermore, ad hoc supply of this kind utilizes capacity – human resources, infrastructure, cold chain – that could be directed towards long-term successful and sustainable rollout. It also dramatically increases the risks of expiry once doses with already short shelf-lives arrive in country, which may have long-term repercussions for vaccine confidence.**

Donations to COVAX, AVAT, and African countries must be made in a way that allows countries to effectively mobilise domestic resources in support of rollout and enables long-term planning to increase coverage rates.

**We call on the international community, particularly donors and manufacturers, to commit to this effort by adhering to the following standards, beginning from 1 January 2022:**

- **Quantity and predictability:** Donor countries should endeavour to release donated doses in large volumes and in a predictable manner, to reduce transaction costs. We acknowledge and welcome the progress being made in this area, but note that the frequency of exceptions to this approach places increased burden on countries, AVAT and COVAX.
- **Earmarking:** These doses should be unearmarked for greatest effectiveness and to support long-term planning. Earmarking makes it far more difficult to allocate supply based on equity, and to account for specific countries' absorptive capacity. It also increases the risk that short shelf-life donations utilise countries' cold chain capacity – capacity that is then unavailable when AVAT or COVAX are allocating doses with longer shelf lives under their own purchase agreements.
- **Shelf life:** As a default, donated doses should have a minimum of 10 weeks shelf life when they arrive in-country, with limited exceptions only where recipient countries indicate willingness and ability to absorb doses with shorter shelf lives.
- **Early notice:** Recipient countries need to be made aware of the availability of donated doses not less than 4 weeks before their tentative arrival in-country.
- **Response times:** All stakeholders should seek to provide rapid response on essential information. This includes essential supply information from manufacturers (total volumes available for donation, shelf life, manufacturing site), confirmation of donation offer from donors, and acceptance/refusal of allocations from countries. Last minute information can further complicate processes, increasing transaction costs, reducing available shelf life and increasing risk of expiry.
- **Ancillaries:** The majority of donations to-date do not include the necessary vaccination supplies such as syringes and diluent, nor do they cover freight costs - meaning these have to be sourced

separately – leading to additional costs, complexity and delay. Donated doses should be accompanied with all essential ancillaries to ensure rapid allocation and absorption...

.....  
.....

## Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### Weekly Epidemiological and Operational updates

Last update: 3 Dec 2021

**Confirmed cases ::** 263 563 622 [259 502 031 week ago]

**Confirmed deaths ::** 5 232 562 [5 183 003 week ago]

**Vaccine doses administered:** 7 864 123 038 [7 702 859 718 week ago]

.....

### Weekly epidemiological update on COVID-19 - 30 November 2021

WHO


Overview

**Globally, weekly COVID-19 case incidence plateaued this week**, with nearly 3.8 million confirmed new cases reported during the week of 22-28 November 2021, similar to the previous week's figures. However, new weekly cases increased in three of the six WHO regions. While global weekly deaths decreased by 10% in the past seven days as compared to the previous week, with over 47 500 new deaths reported, an increase in weekly deaths was reported in two of the six regions. As of 28 November, over 260 million confirmed cases and nearly 5.2 million deaths have been reported globally.

In this edition, we provide:

- Details on the newly designated SARS-CoV-2 Variant of Concern (VOC) Omicron (B.1.1.529)
- Updates on the geographic distribution of VOCs
- A summary of phenotypic characteristics (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance) of VOCs based on available studies.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 28 November 2021\*\*



\*\*See Annex 3: Data, table, and figure notes



## **WHO Director General Speeches** [selected]

<https://www.who.int/director-general/speeches>

*Selected*

1 December 2021

Speech

**[WHO Director-General's closing remarks at the Special Session of the World Health Assembly - 01 December 2021](#)**

*[See WHASS above for detail]*

1 December 2021

Speech

**[WHO Director-General's opening remarks for World AIDS Day 2021 - 1 December 2021](#)**

1 December 2021

Speech

**[WHO Director-General's opening remarks at the media briefing on COVID-19 - 1 December 2021](#)**

- Today, WHO's Member States decided to embark on the process of drafting and negotiating a new convention, agreement or other international instrument on pandemic prevention, preparedness and response.
- The emergence of the Omicron variant has understandably captured global attention. At least 23 countries from five of six WHO regions have now reported cases of Omicron, and we expect that number to grow.
- We call on all countries to take rational, proportional risk-reduction measures, in keeping with the International Health Regulations.
- We must not forget that we are already dealing with a highly transmissible, dangerous variant – the Delta variant, which currently accounts for almost all cases globally. Globally, we have a toxic mix of low vaccine coverage, and very low testing – a recipe for breeding and amplifying variants.
- As we mark World AIDS Day, we are reminded that more than 40 years into the global AIDS epidemic, we still have no vaccine and no cure for this disease. Two years into the COVID-19 pandemic, we have not one but many vaccines, and many other effective tools.

30 November 2021

Speech

**[WHO Director-General's panel remarks - Trends for a Changing World: COVID-19 - the Importance of universal health coverage and primary health care](#)**

30 November 2021

Remarks

**[WHO Director-General's opening remarks at the Member State Information Session on the Omicron variant of SARS-CoV-2](#)**

29 November 2021

Speech

## WHO Director-General's opening remarks at the Special Session of the World Health Assembly - 29 November 2021



## Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 11 November 2021

For 24 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title link above]

| Vaccines | Guidance Document<br>11 November 2021 |
|----------|---------------------------------------|
|----------|---------------------------------------|

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

|    | Manufacturer / WHO EUL holder      | Name of Vaccine                         | NRA of Record   | Platform  | EOI accepted | Pre-submission meeting held | Dossier accepted for review*  | Status of assessment**  | Decision date***   |
|----|------------------------------------|---|-----------------|---|--------------|-----------------------------|---|---|--|
| 1. | BioNTech Manufacturing GmbH        | BNT162b2/COMIRNATY<br>Tozinameran (INN) | EMA             | Nucleoside modified mRNA  | ✓            | ✓                           | ✓   | Finalized:<br>– Baxter Oncology GmbH Germany (DP)<br>– Novartis Switzerland<br>– Milbe (Dermapharm) Germany (DP)<br>– Delpharm, Saint-Remy FRANCE (DP)<br>– Shelf life extension: 09 months at -70 to -90°C<br>– Sanofi-Aventis Deutschland GmbH Germany<br>Diluent suppliers:<br>– Pfizer Perth, Australia/Fresenius Kabi, USA | 31/12/2020<br><br>30/06/2021<br>08/07/2021<br>16/07/2021<br>17/09/2021<br>20/09/2021<br>06/10/2021<br><br>18/06/2021 |
|    |                                    |   | USFDA           |   |              |                             | ✓   | Finalized:<br>– Pharmacia & Upjohn, Kalamazoo (DP)PGS<br>McPherson (DP)<br>– Exelex, Inc. Indianapolis USA  | 16/07/2021<br>16/07/2021<br>30/09/2021   |
| 2. |                                    | AZD1222 Vaxzevria                       | EMA             | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.                                 | ✓            | ✓                           | ✓   | Core data finalized   | 16 April 2021  |
| 3. | AstraZeneca, AB                    | AZD1222 Vaxzevria                       | MFDS KOREA      | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.                                 | ✓            | ✓                           | ✓   | Finalized: Additional sites:<br>– SK-Catalent<br>– Wuxi (DS)<br>– Chemo Spain<br>– Amylin Ohio US (DP)  | 16 April 2021<br>30 April 2021<br>04 June 2021<br>23 July 2021   |
| 4. |                                    | AZD1222 Vaxzevria                       | Japan MHLW/PMDA |   | ✓            | ✓                           | ✓   | Finalized<br>Additional sites:<br>Nipro Pharma Corporation Ise, Japan   | 09 July 2021<br><br><b>11 October</b>  |
| 5. |                                    | AZD1222 Vaxzevria                       | Australia TGA   | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.                                 | ✓            | ✓                           | ✓   | Finalized<br>Additional site:<br>Siam Bioscience Co., Ltd Thailand  | 09 July 2021<br><br>11 October 2021  |
| 6. |                                    |   |                 |   | ✓            | ✓                           | ✓   |   |  |
| 7. | Serum Institute of India Pvt. Ltd. | Covishield<br>(ChAdOx1_nCoV-19)         | DCGI            | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.                                 | ✓            | ✓                           | ✓   | Finalized<br>DS and DP Manjari Bk Pune  | 15 Feb 2021<br>12 Nov 2021   |
| 8. | Janssen-Cilag International NV     | Ad26.COV2.5                             | EMA             | Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein | ✓            | ✓                           | ✓   | Core data finalized (US+NL sites)   | 12 March 2021  |
|    |                                    |   |                 |   |              |                             | Additional sites:<br>– Merck, Durham, UK (DS)<br>–<br>– Merck, West Point/PA (DP) | Finalized<br>– Aspen RSA (DP)<br>– Catalent Agnani Italy (DP)<br>– Future submission<br>– Merck, West Point/PA (DP)   | –25 June 2021<br>– 02 July 2021<br>– As submitted<br>– 05 November 2021  |

| Vaccines |   |   |             |   | Guidance Document<br>11 November 2021 |   |  |  |   |
|----------|---|---|-------------|---|---------------------------------------|---|--|--|---|
|          | Manufacturer / WHO EUL holder   | Name of Vaccine   |             | Platform  | EOI accepted                          | Pre-submission meeting held                         | Dossier accepted for review*           | Status of assessment**   | Decision date***  |
| 9.       | Moderna Biotech   | mRNA-1273   |             | mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)                                       |                                       | ✓   | ✓                                      | Finalized  | 30 April 2021   |
|          |   |   | USFDA       | mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)                                       | ✓                                     | ✓   | ✓                                      | Finalized ModernaTx, Norwood (DS)<br>- Catalent Indiana, LLC (DP)<br>- Lonza Biologics, Inc. Portsmouth, USA (DS)<br>- Baxter, Bloomington, USA (DP) | 06 August 2021  |
| 10.      | Sinopharm / BIBP <sup>1</sup>   | SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)   | NMPA        |   | ✓                                     | ✓   | ✓                                      | Finalized 2 and 5 dose presentation (new manufacturing site)   | 07 May 2021<br>TBC after ongoing inspection   |
| 11.      | SINOVAC<br>Sinovac Life Sciences Co., Ltd.<br>Sinovac Life Sciences Co., Ltd. | COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac <sup>TM</sup>                                       | NMPA        | Inactivated, produced in Vero cells   | ✓                                     | ✓   |  | Finalized 2 dose presentation  | 01 June 2021<br>30 September 2021   |
| 12.      | THE RAMALEYA NATIONAL CENTER  | Sputnik V   | Russian NRA | Human Adenovirus Vector-based Covid-19 vaccine  | Additional information submitted      | Several meetings have been and continue to be held. | "Rolling" submission incomplete.       | Process restarted, awaiting completion of rolling submission and CAPAs to last inspection-   | Anticipated date will be set once all data is submitted and follow-up of inspection observations completed. |
| 13.      | BHARAT BIOTECH  | SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN  | DCGI        | Whole-Virion Inactivated Vero Cell  | ✓                                     | ✓   | ✓                                      | Finalized  | 03 November 2021  |
| 14.      | Sinopharm / WIBP <sup>2</sup>   | Inactivated SARS-CoV-2 Vaccine (Vero Cell)  | NMPA        | Inactivated, produced in Vero cells   | ✓                                     | ✓   | Rolling data started 23 July 2021      | Ongoing  | To be confirmed   |
| 15.      | 康希诺生物<br>CanSinoBio   | Ad5-nCoV  | NMPA        | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)                                  | ✓                                     | ✓   | Rolling data started 09 August 2021    | Ongoing; inspection ongoing  | TBC   |
| 16.      | NOVAVAX   | NVX-CoV2373/Covovax   | EMA         | Recombinant nanoparticle prefusion spike protein formulated with Matrix-M <sup>TM</sup> adjuvant. | ✓                                     | ✓   | Rolling data started 19 August 2021    | Ongoing  | TBC   |
| 17.      | SANOFI  | CoV2 preS dTM-AS03 vaccine  | EMA         | Recombinant, adjuvanted   | ✓                                     |   | Rolling data started 30 July 2021      | Ongoing  | TBC   |
| 18.      | BIHAR INSTITUTE OF INDIA PVT. LTD.<br>Crisis Response Center                  | NVX-CoV2373/Covovax   | DCGI        | Recombinant nanoparticle prefusion spike protein formulated with Matrix-M <sup>TM</sup> adjuvant. | ✓                                     |   | Rolling data started 21 September 2021 | Ongoing  | TBC   |
| 19.      | Clover Biopharmaceuticals   | SCB-2019  | NMPA        | Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein                                      | ✓                                     | ✓   | Rolling data started 20 September      | Screened and communicated gaps. Data awaited   |   |
| 20.      | CUREVAC   | Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101 | EMA         | mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)                                       | ✓                                     | Application withdrawn by manufacturer               |  |  |   |
| 21.      | Zhifei Longcom, China   | Recombinant Novel Coronavirus Vaccine (CHO Cell)  | NMPA        | Recombinant protein subunit   | ✓                                     | Presubmission planned                               |  |  |   |

| Vaccines |  |  |               |   | Guidance Document<br>11 November 2021                          |                             |                              |                        |                  |
|----------|--|--|---------------|---|--|-----------------------------|------------------------------|------------------------|------------------|
|          | Manufacturer / WHO EUL holder                              | Name of Vaccine                                | NRA of Record | Platform  | EOI accepted   | Pre-submission meeting held | Dossier accepted for review* | Status of assessment** | Decision date*** |
| 22.      | Vector State Research Centre of Virology and Biotechnology | EpiVacCorona                                   | Russian NRA   | Peptide antigen   | Letter received not EOI. Reply sent on 15/01/2021              |                             |                              |                        |                  |
| 23.      | IMBCAMS, China   | SARS-CoV-2 Vaccine, Inactivated (Vero Cell)    | NMPA          | Inactivated   | Not accepted, still under initial development                  |                             |                              |                        |                  |
| 24.      | BioCubaFarma - Cuba  | Soberana 01, Soberana 02, Soberana Plus Abdala | CECMED        | SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum | Awaiting information on strategy and timelines for submission. |                             |                              |                        |                  |

1. Beijing Institute of Biological Products Co-Ltd  
2. Wuhan Institute of Biological Products Co Ltd

\* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

\*\*Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

\*\*\* Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

.....

## COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

### AstraZeneca

Press Releases - No new digest announcements identified

### Bharat Biotech

Press Releases - No new digest announcements identified

### BioCubaFarma – Cuba

Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

### CanSinoBio

News - [Website not responding at inquiry]



## **Clover Biopharmaceuticals - China**

News - No new digest announcements identified

## **Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

## **Gamaleya National Center**

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

## **IMBCAMS, China**

Home - No new digest announcements identified

## **Janssen/JNJ**

Press Releases

Dec 03, 2021

United States

**[Janssen to Showcase Progress on Respiratory Syncytial Virus \(RSV\) Vaccine Candidate at ESWI 2021](#)**

Nov 29, 2021

United States

**[Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant](#)**

Since the emergence of the COVID-19 pandemic, Johnson & Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as needed...

## **Moderna**

Press Releases

December 1, 2021

**[Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna's COVID-19 Vaccine in 2022 and 2023](#)**

*Agreement includes 29 million doses for delivery in 2022 and 31 million doses for delivery in 2023*

## **Novavax**

Press Releases

**[Novavax Statement on Omicron Variant Response](#)**

Dec 2, 2021

Novavax is rapidly responding to the emergence of the latest potential threat of the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC). The company is executing a two-pronged variant strategy.

First, Novavax is evaluating its vaccine against the Omicron variant, as the company has done for previous variants including Alpha, Beta and Delta. Second, Novavax has initiated development of an Omicron-specific vaccine construct...

## **Pfizer**

Recent Press Releases - No new digest announcements identified

## **Sanofi Pasteur**

Press Releases

[\*\*Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates\*\*](#)

December 01 2021

*Broad pipeline of innovative vaccines, with a total of 10 candidates planned to advance into the clinic by 2025, six of which will leverage the recently established mRNA Center of Excellence*

## **Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

## **Sinopharm/WIBPBIBP**

News - No new digest announcements identified

## **Sinovac**

Press Releases

[\*\*Instituto Butantan and SINOVAC will hold 'CoronaVac® Symposium' international event about efficacy and security of CoronaVac®\*\*](#)

2021/11/2

## **Vector State Research Centre of Virology and Biotechnology**

Home - No new digest announcements identified

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

## **GSK**

Press releases for media

02 December 2021

[\*\*GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children\*\*](#)

Gavi to provide funding for procurement and introduction of malaria vaccines into child immunisation programmes in Gavi eligible countries.

02 December 2021

[\*\*GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease\*\*](#)

:: Major new collaboration aims to deepen understanding of complex diseases such as Alzheimer's and Parkinson's, and increase drug discovery and development success rates

:: New Institute to be based at Oxford's Nuffield Department of Medicine

02 December 2021

**[Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant](#)**

:: Data to be confirmed by further in vitro pseudo-virus testing

30 November 2021

**[GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&D](#)**

Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D on 3 December 2021

**Merck**

*[News releases](#)*

**[U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE™ \(Pneumococcal 15-valent Conjugate Vaccine\) for Use in Infants and Children](#)**

December 3, 2021

**[Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults](#)**

November 30, 2021

**Novartis**

*[News](#) - No new digest announcements identified*

**SK Biosciences**

*[Press releases](#) - No new digest announcements identified*

**Valneva**

*[Press Releases](#)*

December 3, 2021

**[Valneva Comments on COV-Boost Clinical Trial Data](#)**

December 2, 2021

**[Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001](#)**

November 29, 2021

**[Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001](#)**

.....  
.....

**[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 4 Dec 2021](#)**

*An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]*

**28**vaccines **approved for use** by at least one national regulatory authority <sup>1</sup>**8**vaccines in WHO's **Emergency Use Listing****21.2bn**doses **secured globally****\$2 - \$37**reported vaccine **price range** per dose**5.59bn**doses **COVAX has secured, optioned, or received as donations****601.7M**doses **shipped through COVAX** to **144** countries

■■■■■

■■■■■

### IMF-WHO Vaccine Supply Forecast Dashboard

*Updated on 22 November 2021*

Many countries are not on track to meet the 40% vaccine coverage target. To make progress towards this target, we must identify: (1) Where and in which countries are the gaps?, and (2) How can gaps be addressed?

The IMF-WHO COVID-19 Vaccine Supply Forecast Dashboard estimates expected month vaccine supply until the end of 2021 by country, product and channel. The tracker builds on the work of the IMF Staff Discussion Note – A Proposal to End the COVID-19 Pandemic (Agarwal and Gopinath, 2021).

## 3. Gap to 40% and Excess Doses by Country Group

End-Dec

End-Nov

End-Oct

End-Sep

Baseline Scenario

Low Supply Scenario

High Supply Scenario

#### Gap to 40% expected coverage

|  | World | AMC91 | High Income Countries | UMIC (excl. China) |
|--|-------|-------|-----------------------|--------------------|
| Number of countries not on track to reach 40% coverage               | 73    | 60    | 0                     | 13                 |
| Number of doses (mn.) needed for all countries to reach 40% coverage | 563   | 539   | 0                     | 24                 |

#### Excess doses above 100% expected coverage

|   |     |   |     |    |
|---|-----|---|-----|----|
| Number of countries on track to reach above 100% coverage | 48  | 3 | 39  | 5  |
| Number of excess doses (mn.) expected above 100% coverage | 637 | 0 | 474 | 77 |

■■■■■

■■■■■

## Duke – Launch and Scale Speedometer


### [The Race for Global COVID-19 Vaccine Equity](#)

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)



Data updated on December 1st 2021.





## Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 4 Dec 2021]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)





.....  
.....

## COVID Vaccines – OCHA:: HDX

### [COVID-19 Data Explorer: Global Humanitarian Operations](#)

#### **COVID-19 Vaccine Roll-out**

**4 Dec 2021** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 263M total confirmed cases; 5.2M total confirmed deaths**

**Global vaccines administered: 8.078B**

Number of Countries: 30 [30 week ago]

COVAX Allocations Round 4-9 (Number of Doses): 220M [220M week ago]

COVAX Delivered (Number of Doses): 180M [170M week ago]

Other Delivered (Number of Doses): 300M [280M week ago]

Total Delivered (Number of Doses): 480M [450M week ago]






## Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **4 Dec 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....  
.....

### ***Our World in Data***

#### **Coronavirus (COVID-19) Vaccinations** [Accessed 4 Dec 2021]

:: [54.9%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [8.14 billion doses](#) have been administered globally, and [34.41 million](#) are now administered each day.

:: Only [6.2%](#) of people in low-income countries have received at least one dose.

#### Share of the population fully vaccinated against COVID-19, Dec 3, 2021

Our World  
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data – Last updated 4 December 2021, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


▶ Dec 13, 2020 ◯ Dec 3, 2021

## Share of the population fully vaccinated against COVID-19, Dec 3, 2021

Our World  
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 4 December 2021, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Dec 3, 2021

.....  
.....

### U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

#### FDA

##### *Press Announcements*

[December 3, 2021 - FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns](#)

[November 30, 2021 - Coronavirus \(COVID-19\) Update: November 30, 2021](#)

[November 30, 2021 - Coronavirus \(COVID-19\) Update: FDA Actively Working to Investigate, Address Potential Impacts of Omicron Variant; Urges Vaccination and Boosters](#)

### Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

*No meetings on [calendar](#)*

.....

## **White House [U.S.]**

*Briefing Room – Selected Major COVID Announcements*

**[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)**

December 03, 2021 Press Briefings

**[Remarks by President Biden on the COVID-19 Winter Plan](#)**

December 02, 2021 Speeches and Remarks

**[Background Press Call by Senior Administration Officials on New Actions to Protect Americans Against the Delta and Omicron Variants This Winter](#)**

December 02, 2021 Press Briefings

**[President Biden Announces New Actions to Protect Americans Against the Delta and Omicron Variants as We Battle COVID-19 this Winter](#)**

December 02, 2021 Statements and Releases

**[Statement from White House COVID-19 Response Coordinator Jeff Zients on First Case of the Omicron COVID-19 Variant in the United States](#)**

December 01, 2021 • Statements and Releases

**[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)**

November 30, 2021 • Press Briefings

**[Readout of President Biden's Meeting with COVID-19 Response Team on the Omicron Variant](#)**

November 28, 2021 Statements and Releases

## **U.S. Department of State**

<https://www.state.gov/coronavirus/releases/>

*Media Notes*

*Press Statement*

**[Gayle Smith's Service as the Coordinator for Global COVID-19 Response and Health Security](#)**

Antony J. Blinken November 30, 2021

.....

.....

## **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **European Medicines Agency**

*News & Press Releases*

**News: ICMRA and WHO map out flexibilities used by regulators to respond to the COVID-19 pandemic (new)**

Last updated: 03/12/2021

*[See Milestones above for detail]*

**News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021 (new)**

PRAC, Last updated: 03/12/2021

*PRAC update on risk of myocarditis and pericarditis with mRNA vaccines*

**News: EMA starts rolling review of Valneva's COVID-19 vaccine (VLA2001) (new)**

CHMP, Last updated: 02/12/2021

**News: Increase in manufacturing capacity for COVID-19 vaccine from AstraZeneca (new)**

CHMP, Last updated: 01/12/2021

.....

**European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*Latest Updates*

*Publication & Data*

**Epidemiological update: Omicron variant of concern (VOC) – data as of 4 December 2021 (12.00)**

*Epidemiological update*

4 Dec 2021

As of 4 December and since 3 December 2021, 58 additional SARS-CoV-2 Omicron variant of concern (VOC) cases have been confirmed in the European Union and European Economic Area (EU/EEA), contributing to an overall total of 167 confirmed cases so far.

**Cases have been reported by 17 countries:** Austria (10), Belgium (6), Czechia (1), Denmark (18), Finland (1), France (12, including 2 in Reunion), Germany (15), Greece (1), Iceland (7), Ireland (1), Italy (9), Luxembourg (1), the Netherlands (18), Norway (19), Portugal (34), Spain (7) and Sweden (7) according to information from public sources. One new EU/EEA country (Luxembourg) has reported the Omicron variant and a number of probable cases are currently under investigation in several countries.

**The majority of confirmed cases have a history of travel to countries in Africa**, with some having taken connecting flights at other locations between Africa and Europe.

**Several EU/EEA countries (Belgium, Germany, Spain) detected cases without an epidemiological link to areas where community transmission of the Omicron variant is documented or presumed.** This indicates that undetected community transmission could be ongoing in these countries. Finland reported cases with travel history within the EU/EEA (Sweden, Denmark).

All cases for which there is available information on severity were either asymptomatic or mild. No deaths have been reported among these cases so far. These figures should be assessed with caution as the number of confirmed cases is too low to understand if the disease clinical spectrum of Omicron differs from that of previously detected variants.

.....



## European Centre for Disease Prevention and Control

### COVID-19 Vaccine Tracker

| Cumulative uptake of at least one dose in the total population in EU/EEA | Cumulative uptake of full vaccination in the total population in EU/EEA |
|--|---|
| 70.7%  | 66.3%   |

*Accessed 4 Dec 2021*

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

### European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

*Statement* 1 December 2021

### [Statement by President von der Leyen on facing current and new COVID-19 challenges](#)

*Press release* 1 December 2021

### [Commission reiterates calls to step up vaccination, rapid deployment of boosters, vigilance and rapid reaction to Omicron variant](#)

The Commission is today putting forward a common and coordinated EU approach to address effectively the challenges from the resurgence of COVID-19 in many Member States this autumn.

There are rapidly rising case numbers and a renewed pressure on hospitals, which calls for urgent and determined action. The new potential threat from the Omicron variant is adding to these concerns, and underlines the importance of tackling the pandemic to progress towards long-term health security, both in the EU and globally...

*Press release* 30 November 2021

### [European Health Union: Commission welcomes agreement on a stronger European Centre for Disease Prevention and Control](#)

Last night, the European Parliament and the Council reached an agreement on a reinforced role for the European Centre for Disease Prevention and Control (ECDC). The revised ECDC mandate will allow the agency to take a stronger role in supporting the EU and its Member States in the prevention and control of communicable disease threats and improve European preparedness for future health challenges...

*Statement* 26 November 2021


### [Press statement by President von der Leyen on the new COVID variant](#)

Commission President von der Leyen has given a press statement on the new COVID variant.

.....

.....

## Africa: COVID-19 – Announcements/Regulatory Actions/Deployment



Accessed 4 Dec 2021. Full scale, interactive dashboard available at:  
<https://africacdc.org/covid-19-vaccination/>

.....  
.....

## Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[RDIF signs agreements with partners in Vietnam to expand production of the Russian Sputnik V vaccine](#)

Press release, 01.12.2021

[The one-shot Sputnik Light vaccine authorized in UAE as a universal booster shot](#)

Press release, 30.11.2021



## **Statement of RDIF and the Gamaleya Institute on Omicron variant of COVID**

Press release, 29.11.2021

"...The Gamaleya Institute believes both Sputnik V and Sputnik Light will neutralize the latest Omicron variant and has started the necessary studies.

Nonetheless the Gamaleya Institute, based on existing protocols of immediately developing vaccine versions for variants of concern, has already begun developing the new version of Sputnik vaccine adapted to Omicron. In an unlikely case such modification is needed, the new Sputnik Omicron version can be ready for mass-scale production in 45 days. Several hundred million Sputnik Omicron boosters can be provided to international markets already by Feb 20, 2022 with over 3 billion doses available in 2022."

.....  
.....

## **India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **Ministry of Health and Family Welfare**

<https://www.mohfw.gov.in/>

**Active** (0.29%)

**99974** (2↓)

**Discharged** (98.35%)

**34053856** (8190↑)

**Deaths** (1.36%)

**470530** (415↑)

**Total Vaccination : 1,26,53,44,975 (73,63,706↑)**

03.12.2021 [FAQs on SARS-CoV-2 Variant-Omicron](#)

### **Government of India – Press Information Bureau**

*Latest Press Releases*

#### **COVID-19 Vaccination Update - Day 323**

:: India's cumulative vaccination coverage crosses 127 crore landmark milestone

:: More than 93 lakh Vaccine doses administered today till 7 pm

*Posted On: 04 DEC 2021 8:09PM by PIB Delhi*

### **Indian Council for Medical Research (ICMR)**

<https://www.icmr.gov.in/media.html>

*Press Releases*

*No new digest content identified.*

.....  
.....

## **China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

## **National Health Commission of the People's Republic of China [to 4 Dec 2021]**

<http://en.nhc.gov.cn/>

*News*

### **Dec 4: Daily briefing on novel coronavirus cases in China**

On Dec 3, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 90 new cases of confirmed infections.

### **China has provided over 1.8b COVID-19 vaccine doses to international community**

2021-12-03

BEIJING - To date, China has provided over 1.8 billion doses of COVID-19 vaccines to more than 120 countries and international organizations.

China has delivered on its promise to make vaccines global public goods, and made continued efforts to improve vaccine accessibility and affordability in developing countries.

China has pledged to strive to provide a total of 2 billion vaccine doses to the world by the end of this year, and said that in addition to donating \$100 million to COVAX, it would donate 100 million vaccine doses to other developing countries in the course of this year.

As of Nov 12, China has supplied more than 70 million vaccine doses to COVAX and is conducting joint vaccine production with 19 developing countries...

### **China pushing development of vaccine against Omicron**

2021-12-03

China is rapidly advancing development of COVID-19 vaccines targeting the Omicron variant, a health official said during an interview with China Central Television on Thursday.

Zheng Zhongwei, a National Health Commission official who heads China's COVID-19 vaccine development task force, said preliminary analysis suggests that the new strain is more transmissible than the Delta variant, but it is too early to determine if the Omicron variant would diminish the efficacy of existing vaccines.

"We think the majority of vaccines remain effective," he said. "Despite the possibility of some degree of immunity escape, our initial finding is that they still have marked effects on preventing severe diseases and deaths."...

### **China sticks to its strategy in COVID-19 response: official**

2021-12-02

BEIJING -- A health official has emphasized the importance of committing to the current strategy in China to clear COVID-19 infections in a timely manner as highly contagious variants of the virus continue to rage around the world.

Since mid-October, the latest COVID-19 resurgence in China has spread to more than 20 provincial-level regions. Most regions managed to contain the outbreak within an incubation period of about 14 days, said Ma Xiaowei, head of the National Health Commission, in a recent interview with Xinhua.

"We have been thinking, especially during the process of coping with the spread of the Delta variant, how to control the epidemic with more effective measures, lower costs and at faster speeds to minimize its impact on economic and social development and people's lives," Ma said.

He added that the government has also noticed that the epidemic response in some countries, which have not implemented strict epidemic control measures, has not been satisfactory. There have been relapses that severely impacted people's lives, health and the economy and society overall.

As a result, China has been focusing on improving epidemic prevention and early detection, he noted...

.....  
.....  
.....

## ***Emergencies***

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

<https://polioeradication.org/polio-today/polio-now/this-week/>

### **Polio this week as of 01 December 2021**

***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

**Pakistan:** one WPV1 positive environmental sample

**Central African Republic:** one cVDPV2 positive environmental sample

**Nigeria:** seven cVDPV2 positive environmental samples

**Uganda:** one cVDPV2 positive environmental sample

.....  
.....

## **WHO/OCHA Emergencies**

### **Health emergencies list - WHO**

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

**Afghanistan crisis** *[Last apparent update: 18 Oct 2021]*

**Crisis in Northern Ethiopia** *[Last apparent update: 1 June 2021]*

**Ebola outbreak, Democratic Republic of the Congo, 2021** *[Last apparent update: 17 Aug 2021]*

**Ebola outbreak outbreak, N'Zerekore, Guinea, 2021** *[Last apparent update: 17 Aug 2021]*

**Coronavirus disease (COVID-19) pandemic** *[See COVID above]*

**Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020**

*[Last apparent update: 17 Aug 2021]*

**Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020**

*[Last apparent update: 17 Aug 2021]*

**Ebola outbreak, Democratic Republic of the Congo, 2018** *[Last apparent update: 24 July 2018]*

**Yemen crisis** *[Last apparent update: 12 February 2021]*

**Syria crisis** *[Last apparent update: 18 June 2021]*

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 1 Oct 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) [Last apparent update: 17 Aug 2021]

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 17 Aug 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 13 September 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

#### [UN OCHA – Current Emergencies](#)

*Current Corporate Emergencies*

##### ***Afghanistan***

[No new digest content identified]

##### ***Northern Ethiopia***

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 2 Dec 2021](#)

.....

.....

#### **WHO & Regional Offices** [to 4 Dec 2021]

<https://www.who.int/>

*Selected News, Statements*

3 December 2021

*Procurement*

[Request for proposal: Technical support to SAGE executive secretariat](#)

3 December 2021

*Departmental news*

[South-East Asia: Influenza virus sharing in a time of COVID-19](#)

3 December 2021

*Departmental news*

[Global and regional support for the 2021–2022 influenza season](#)

3 December 2021

*Departmental news*

**[Critical evidence to strengthen seasonal vaccination in the Americas](#)**

2 December 2021

*Departmental news*

**[Botswana is first country with severe HIV epidemic to reach key milestone in the elimination of mother-to-child HIV transmission](#)**

1 December 2021

*Joint News Release*

**[World AIDS Day 2021 - Step up, be bold, end AIDS, end inequalities and end pandemics](#)**

1 December 2021

*Joint News Release*

**[Tripartite and UNEP support OHHLEP's definition of "One Health"](#)**

1 December 2021

*News release*

**[World Health Assembly agrees to launch process to develop historic global accord on pandemic prevention, preparedness and response](#)**

1 December 2021

*Departmental news*

**[It's time for action on inequality to end TB and AIDS](#)**

30 November 2021

*Departmental news*

**[WHO Pandemic Ethics & Policy Summit](#)**

29 November 2021

*Joint News Release*

**[Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries](#)**

.....

**[Weekly Epidemiological Record, Vol. 96, No. 48, pp. 585–596 3 December 2021](#)**

:: Schistosomiasis and soil-transmitted helminthiasis: progress report, 2020

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: [Africa steps up Omicron variant detection as COVID-19 cases rise in southern Africa](#) 02 December 2021

:: Botswana is first country with severe HIV epidemic to reach key milestone in the elimination of mother-to-child HIV transmission 02 December 2021

:: WHO stands with African nations and calls for borders to remain open 28 November 2021

### **WHO Region of the Americas PAHO**

*No new digest content identified*

### **WHO South-East Asia Region SEARO**

:: 1 December 2021 Statement- World AIDS Day

:: 27 November 2021 News release

WHO asks countries in South-East Asia Region to be vigilant as cases surge globally and new Variant of Concern is detected

### **WHO European Region EURO**

:: What you need to know about the new Omicron COVID-19 variant 03-12-2021

:: Greece: civil society reduces barriers to health and education for young people with disabilities during the pandemic 03-12-2021

:: WHO/Europe high-level experts complete mission in Turkmenistan to strengthen health system preparedness 01-12-2021

:: Urgent need to take preventive measures in the fight against COVID-19 the focus of WHO/Europe advocacy campaign 30-11-2021

:: Building trust helps United Kingdom chart a path towards eliminating AIDS by 2030 30-11-2021

### **WHO Eastern Mediterranean Region EMRO**

:: World AIDS Day: Reaching more people with HIV services and reducing inequalities 1 December 2021

### **WHO Western Pacific Region**

:: 3 December 2021 Regional Director's remarks at the virtual press conference on 3 December 2021

.....

### **WHO Events**

<https://www.who.int/news-room/events/2>

*[Selected]*

### **[Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization \(SAGE\) – 7 December 2021](#)**

7 December 2021

This extraordinary virtual meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will take place on Tuesday 7 December 2021 to propose recommendations to WHO on the use of COVID-19 vaccine(s).

Agenda: [https://cdn.who.int/media/docs/default-source/immunization/sage/2021/december/sage-agenda-7dece2021-virtual-draft-rev26nov.pdf?sfvrsn=f2b71e9f\\_10](https://cdn.who.int/media/docs/default-source/immunization/sage/2021/december/sage-agenda-7dece2021-virtual-draft-rev26nov.pdf?sfvrsn=f2b71e9f_10)

### **[Building stronger, sustainable, equitable societies for pandemic prevention and for navigating the response to the COVID-19 crisis](#)**

7 December 2021 12:00 – 13:00 CET

Join us to launch the new WHO evidence brief, "COVID-19 and the social determinants of health and health equity", and to discuss the implications of the impacts of the social determinants of health equity for pandemic prevention, preparedness, response, and recovery.

\* Tuesday 7 December 2021 \* 12:00-13:00 Central European Time \*

\* Join via Zoom \* <https://who.zoom.us/j/96260096854>

Password: Yt@W21bZ

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

### *Selected Titles*

1 December 2021

#### **[Global vaccine safety blueprint 2.0 \(GVSB2.0\) 2021-2023](#)**

##### *Overview*

This Global Vaccines Safety Blueprint 2.0 (GVSB2.0) was developed through a step-wise consensus process to define the strategic priorities and objectives in the area of vaccines safety for 2021 to 2023 and beyond. The overall vision, goals and operating principles for a vaccine safety monitoring system described in the GVSB2.0 are equally relevant for medicines and for building product-agnostic pharmacovigilance systems in countries. Where possible, we need to build common systems and approaches that are smart, product-agnostic, address common needs and advance the principles of work-sharing and reliance to take into consideration competing priorities in resource-limited settings. For example, how we collect and manage data (databases) may not be very different between vaccines and medicines; on the other hand, the principles of benefit risk assessment and how risks are communicated requires specialized and perceptive handling for vaccines.

PDF: <https://apps.who.int/iris/rest/bitstreams/1392676/retrieve>

1 December 2021

#### **[Global vaccine safety blueprint 2.0 background research](#)**

30 November 2021

#### **[Global progress report on WASH in health care facilities: Fundamentals first](#)**

30 November 2021

#### **[Framework for countries to achieve an integrated continuum of long-term care](#)**

30 November 2021

#### **[Approaches to enhance and accelerate study of new drugs for HIV and associated infections in pregnant...](#)**

29 November 2021

#### **[COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: ethical considerations](#)**

##### *Overview*

##### *Executive Summary*

In June 2020, global regulators convened under the auspices of the International Coalition of Medicines Regulatory Authorities (ICMRA) and co-chaired jointly by the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) reached consensus on the study design

requirements for Phase 3 COVID-19 vaccine clinical trials. The ICMRA noted that phase 3 clinical trials should be randomized, double-blinded and controlled with a placebo or active comparators. In September 2020, the World Health Organization (WHO ) advised: "Phase IIB/III efficacy trials should be randomized, double-blinded and placebo controlled." Since then, multiple COVID-19 vaccines have been authorized worldwide based on interim results of pivotal placebo-controlled efficacy trials, and billions of COVID-19 vaccine doses have been administered under emergency use/conditional marketing authorization or full approval regulatory mechanisms.

In December 2020, a WHO expert group advised that the placebo control arms of COVID-19 vaccine trials should be progressively unblinded as authorized vaccines become available in the community hosting the trial, starting with prioritized groups.

Before a COVID-19 vaccine trial commences enrolment, if one or more authorized/approved COVID-19 vaccine is locally available and the participant meets programmatic eligibility criteria, the study team should advise the participant that they are eligible to receive the authorized vaccine(s). Participants may elect to receive the authorized vaccine at any point in the trial.

The appropriateness of conducting a placebo control trial may depend on whether the candidate vaccine is a prototype vaccine, modified vaccine or next generation vaccine

PDF: <https://apps.who.int/iris/rest/bitstreams/1396234/retrieve>

26 November 2021

### **[Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus](#)**

.....  
.....

**CDC/ACIP [U.S.]** [to 4 Dec 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements [Selected]*

### **[CDC Tightens Testing Requirement for International Travel to the US to One Day](#)**

Friday, December 3, 2021

### **[Public Health Authorities Investigating Additional Confirmed Case of COVID-19 Caused by the Omicron Variant](#)**

Thursday, December 2, 2021

### **[First Confirmed Case of Omicron Variant Detected in the United States](#)**

Wednesday, December 1, 2021

### **[New CDC Vital Signs Report Reveals a Decade of Continuing HIV Inequities on Eve of World AIDS Day](#)**

Tuesday, November 30, 2021

### **[CDC Expands COVID-19 Booster Recommendations](#)**

Monday, November 29, 2021

### **[ACIP Meetings](#)**

*No new meetings listed.*



## **MMWR News Synopsis Friday, December 3, 2021**

### *Selected Content*

:: Symptoms of Depression, Anxiety, Post-Traumatic Stress Disorder, and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers During the COVID-19 Pandemic — United States, March–April 2021

:: Vital Signs: HIV Infection, Diagnosis, Treatment, and Prevention Among Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2010–2019

:: Correction and Republication: Symptoms of Depression, Anxiety, Post-Traumatic Stress Disorder, and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers During the COVID-19 Pandemic — United States, March–April 2021

## **Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 25 announcements/reports/data summaries.*

:: 3 Dec CDC Tightens Testing Requirement for International Travel to the US to One Day

:: 3 Dec Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 03 Dec 2021 06:00:00 EST

.....  
.....

**Africa CDC** [to 4 Dec 2021]

<http://www.africacdc.org/>

*News*

*Press Releases*

**Africa Centres for Disease Control and Prevention's Statement regarding the new SARS-COV-2 virus variant B.1.1.529**

26 November 2021

*Press Releases*

**Mastercard Foundation and Africa CDC's Saving Lives and Livelihoods initiative delivers first tranche of over 15 million vaccines**

ADDIS ABABA, ETHIOPIA, 25 November 2021 — The Mastercard Foundation and Africa CDC jointly announced that 15.2 million vaccines purchased under the Saving Lives and Livelihoods initiative are currently being distributed across Africa. Through Saving Lives and Livelihoods, the Mastercard Foundation is purchasing vaccines for more than 65 million people. This is the first tranche of vaccines to be delivered under the initiative. The vaccines will be distributed within countries by UNICEF.

Launched in June 2021, Saving Lives and Livelihoods is now a \$1.5 billion partnership that aims to enable vaccination for millions of people, develop a workforce for vaccine manufacturing, and strengthen the Africa CDC's capacity to oversee a historic vaccination campaign and effectively respond to future outbreaks.

"Timely delivery of these vaccines underscores the effectiveness of the African Vaccine Acquisition Trust. Working with the Africa CDC and multiple organizations, the Mastercard Foundation will support the roll out of vaccinations to millions across the continent. More remains to be done to urgently increase vaccination rates. We call on governments, funders, civil society and others to step forward to save lives and livelihoods in Africa," said Reeta Roy, President and CEO of the Mastercard Foundation...

.....  
.....

**China CDC** <http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 4 Dec 2021]

<http://en.nhc.gov.cn/>

*News*

**[Dec 4: Daily briefing on novel coronavirus cases in China](#)**

On Dec 3, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 90 new cases of confirmed infections.

**[China has provided over 1.8b COVID-19 vaccine doses to international community](#)**

2021-12-03

**[China pushing development of vaccine against Omicron](#)**

2021-12-03

**[China sticks to its strategy in COVID-19 response: official](#)**

2021-12-02

**National Medical Products Administration – PRC** [to 4 Dec 2021]

<http://english.nmpa.gov.cn/>

*News*

**[Over 2.5b COVID-19 vaccine doses administered on Chinese mainland](#)**

2021-12-02

Over 2.5 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Nov 30, data from the National Health Commission showed on Dec 1.

**[Xi says China will supply Africa with additional 1 bln COVID-19 vaccine doses](#)**

2021-11-30

Chinese President Xi Jinping on Monday said China will provide an additional 1 billion doses of COVID-19 vaccines to Africa.

**CCDC Weekly - [Weekly Reports: Current Volume \(3\)](#)**

2021-12-03 / No. 49 INFLUENZA ISSUE

[View PDF of this issue](#)

- [Editorial: China CDC Weekly's Second Meeting of the Editorial Board, Advisory Committee, and Editorial Office to Celebrate the Second Anniversary of the Inaugural Issue](#)
- [Methods and Applications: The Incoming Influenza Season — China, the United Kingdom, and the United States, 2021–2022](#)
- [Perspectives: Quo Vadis Influenza?](#)
- [Perspectives: GISAID's Role in Pandemic Response](#)
- [Perspectives: A Tale of Two Cities: From Influenza HxNy to SARS-CoV-z](#)

.....

.....  
.....

## Contents [click to move among sections]

- :: [Milestones - Perspectives](#)
- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

.....  
.....  
.....

## Organization Announcements

### *Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

### **Paul G. Allen Frontiers Group** [to 4 Dec 2021]

<https://alleninstitute.org/news-press/>

#### *News*

#### **[\\$20M awards fund centers' studies of human brain evolution, animal development](#)**

December 2, 2021

Two Allen Discovery Centers enter their next phase of discovery, poised to address large questions about biology

### **BARDA – U.S. Department of HHS** [to 4 Dec 2021]

<https://www.phe.gov/about/barดา/Pages/default.aspx>

#### *News*

*No new digest content identified.*

### **BMGF - Gates Foundation** [to 4 Dec 2021]

<https://www.gatesfoundation.org/ideas/media-center>

#### *Press Releases and Statements*

*No new digest content identified.*

### **Bill & Melinda Gates Medical Research Institute** [to 4 Dec 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 4 Dec 2021]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 4 Dec 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [\*\*Informed Consent: A Monthly Review – December 2021\*\*](#) is now posted [here](#)

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 4 Dec 2021]

<http://cepi.net/>

*Latest News*

[\*\*CEPI and MVC co-fund mix-and-match booster trial of COVID-19 vaccines\*\*](#)

Clinical trial will evaluate heterologous and fractional booster doses – or ‘mix-and-match’ booster - combinations of MVC-COV1901 with other COVID-19 vaccines.

02 Dec 2021

[\*\*Speech made by CEPI CEO, Dr Richard Hatchett, on the emergence of Omicron variant at today’s World Health Assembly special session\*\*](#)

*Dr Richard Hatchett, CEO of CEPI, addressed today’s special session of the World Health Assembly—on behalf of the Access to COVID-19 Tools Accelerator.*

“...South Africa and Botswana’s efficient surveillance, early detection, and warning, and sharing of information have granted the world precious time. Time to implement containment measures and time to prepare. Our industry partners are now intensively investigating whether our current vaccines have been compromised and consulting with regulators and WHO as they develop new ones just in case.

“As you embark on this historic Special Session, I would urge you to keep this example, which is right in front of you, in mind.

“The world is at a crossroads. We know we will face future global infectious disease emergencies and potential pandemic threats. That is a certainty. What happens when these threats materialize, however, is up to us – and in a very tangible sense, up to you.

“We urgently need a global framework or convention on pandemic preparedness and response if we are to have any hope of preventing future pandemics, accelerating the global availability of critical medical countermeasures, and ensuring more just outcomes than we have achieved with COVID...”

**DARPA – Defense Advanced Research Projects Agency** [to 4 Dec 2021]

<https://www.darpa.mil/news>

*News*

*Our Blog*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 4 Dec 2021]

<https://dukeghic.org/>

*Our Blog*

*No new digest content identified.*

**EDCTP** [to 4 Dec 2021]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

01 December 2021

**[World AIDS Day 2021: tackling inequalities](#)**

**Emory Vaccine Center** [to 4 Dec 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 4 Dec 2021]

<http://www.euvaccine.eu/>

*Latest News, Events*

*EVI*

**[World AIDS Day 2021: End inequalities. End AIDS](#)**

1 December 2021 What is world AIDS

**Fondation Merieux** [to 4 Dec 2021]

<http://www.fondation-merieux.org/>

*News, Events*

*Mérieux Foundation co-organized event*

**[8th Meeting of the GTFCC Working Group on Oral Cholera Vaccine](#)**

December 6 - 8, 2021 - Événement virtuel & Centre des Pensières, Veyrier du Lac (France)

**Gavi** [to 4 Dec 2021]

<https://www.gavi.org/>

*News Releases*

3 December 2021

**[Gavi Board approves malaria vaccine programme funding, COVAX 2022 strategic approach and measures to maintain, restore and strengthen routine immunisation](#)**

*[See Week in Review above for detail]*

2 December 2021

**Gavi Board approves funding to support malaria vaccine roll-out in sub-Saharan Africa**

2 December 2021

**New Zealand kicks off 2022 COVAX fundraising efforts with NZ\$ 9 million funding pledge**

29 November 2021

**Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries**

**GHIT Fund** [to 4 Dec 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that  
No new digest content identified.*

**Global Fund** [to 4 Dec 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*News*

**The Next Chapter of Our Fight Against HIV**

01 December 2021 by Peter Sands, Executive Director

**Current Testing Tools Uncompromised by New COVID-19 Variant of Concern Omicron (B.1.1.529)**

29 November 2021

The accuracy of existing molecular (PCR, NAAT) tests appears uncompromised by COVID-19 variant Omicron (B.1.1.529), designated a Variant of Concern by the World Health Organization (WHO) on Friday. Preliminary evidence suggests that this is also true...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 4 Dec 2021]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 4 Dec 2021]

<http://www.hillemanlabs.org/>

*....No "news" page or tab identified.*

**HHMI - Howard Hughes Medical Institute** [to 4 Dec 2021]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified*

### **Human Vaccines Project** [to 4 Dec 2021]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified*

### **IAVI** [to 4 Dec 2021]

<https://www.iavi.org/newsroom>

*Latest News*

December 3, 2021

#### **GreenLight (ENVI) and IAVI begin work on Omicron variant-adapted COVID-19 vaccine candidate**

BOSTON and NEW YORK – DECEMBER 3, 2021 – GreenLight Biosciences (ENVI) and IAVI, a non-profit scientific research organization, today announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.

"The highly mutated Omicron variant may be partially capable of eluding existing vaccines, so rapid adaptation is an urgent priority," said GreenLight CEO Andrey Zarur. "We have started lab work already. We will be testing a new candidate vaccine shortly in preclinical models. We have also begun an analysis on how we would proceed in clinical studies in Africa, in the context of our current clinical plans."

IAVI President and CEO Mark Feinberg said, "While it's impossible to say right now where Omicron first emerged, we wouldn't have been able to respond to this threat so quickly had it not been for the skill and openness of the South African scientists who identified the variant and shared the sequence with the world. Now we must focus on bringing solutions forward both to address this new variant and the stark inequities that remain in the global availability of vaccines to prevent COVID-19."

November 30, 2021

#### **GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa**

- IAVI's extensive clinical trial experience will be combined with GreenLight COVID-19 vaccine candidate.
- Goal is to broaden and accelerate access to messenger RNA (mRNA) COVID-19 vaccines.
- Phase I trial planned for late Q1 2022.
- Plan speeds creation of vaccines in Africa, for Africa, and suitable for use in low-income countries globally.

### **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

### **ICRC** [to 4 Dec 2021]

<https://www.icrc.org/en/whats-new>

*Selected News Releases, Statements, Reports*

### **ICRC: Omicron highlights the need to step up global vaccinations, including in conflict zones**

Statement from Esperanza Martinez, the head of the COVID-19 Crisis Management Team at the ICRC on vaccine inequity.

02-12-2021 | News release

### **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

### **IFRC** [to 4 Dec 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

02/12/2021

**"Impulsive reactions are an affront to the global solidarity we need to successfully respond to a crisis of this scale." [WHA]**

29/11/2021

**"Impulsive and ineffective reactions" to COVID-19's Omicron variant will send more Africans into poverty**

**Mohammed Mukhier, IFRC Regional Director for Africa**

29/11/2021

**"The pandemic has both thrived on inequities and exacerbated them"**

### **Institut Pasteur** [to 4 Dec 2021]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

Press release

26.11.2021

**ComCor study: new results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant**

From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on circumstances and places of infection with the SARS-CoV-2 virus in France. The aim of the study was to identify the socio-demographic factors, places visited and behaviors associated with a higher risk of infection with SARS-CoV-2. The study was also used to carry out a real-world analysis of the effect of previous infection with COVID-19 and the efficacy of messenger RNA vaccines against symptomatic infection with the Delta variant. The findings were published in The Lancet Regional Health Europe on November 26, 2021.

### **IOM / International Organization for Migration** [to 4 Dec 2021]

<http://www.iom.int/press-room/press-releases>



*News - Selected*

*News*

01 Dec 2021

**IOM's World Migration Report Shows Global Displacement Rising Despite COVID-19 Mobility Limits**

**ISC / International Science Council** [to 4 Dec 2021]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News*

[Press releases](#)

**The International Year of Basic Sciences for Sustainable Development proclaimed by the United Nations General Assembly for 2022**

03.12.2021

We need more basic sciences to achieve Agenda 2030 and its 17 Sustainable Development Goals. This is the message sent to the world by the United Nations General Assembly on 2 December 2021: Member States approved by consensus the resolution 76/A/L.12 promulgating the year 2022 as the International Year of Basic Sciences for Sustainable Development (IYBSSD2022).

With this [resolution](#), the United Nations General Assembly 'invites all [its] Member States, organizations of the United Nations system and other global, regional and subregional organizations, as well as other relevant stakeholders, including academia, civil society, inter alia, international and national non-governmental organizations, individuals and the private sector, to observe and raise awareness of the importance of basic sciences for sustainable development, in accordance with national priorities'...

**IVAC** [to 4 Dec 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 4 Dec 2021]

<http://www.ivl.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 4 Dec 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 4 Dec 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

Ukraine

**[Volunteers help fellow villagers access healthcare in conflict-affected eastern Ukraine](#)**

Project Update 3 Dec 2021

*Coronavirus COVID-19 pandemic*

**[In an unequal world, our response to COVID-19 cannot be one size-fits-all](#)**

Opinion 3 Dec 2021

*Myanmar*

**[Myanmar: Political turmoil threatens HIV care](#)**

MSF Asia Pacific. 1 Dec 2021

*HIV/AIDS*

**[DRC: People are still dying unnecessarily from HIV](#)**

Project Update 1 Dec 2021

*World AIDS Day*

**[Why are people living with HIV still dying of AIDS?](#)**

Opinion 1 Dec 2021

*World Health Assembly*

**[Pandemic preparedness and response: some lessons learnt](#)**

Statement 30 Nov 2021

MSF delivered a statement on 30 November 2021 during the World Health Assembly Special Session.

**National Academy of Medicine** - USA [to 4 Dec 2021]

<https://nam.edu/programs/>

*Selected News/Programs/Events*

**[Expert Paper from the National Academy of Medicine Identifies Lessons Learned and Compelling Needs to Center Patients, Families, and Communities in the Delivery of Health and Health Care After COVID-19](#)**

November 29, 2021

WASHINGTON – An individually-authored discussion paper was published in NAM Perspectives today that focuses on the experience and needs of patients, families, and communities, was published on November 29, 2021. Patients, Families, and Communities COVID-19 Impact Assessment: Lessons Learned and Compelling Needs reviews the impact and implications of COVID-19 on patients, families, and communities, offers [...]

**National Academy of Sciences** - USA [to 4 Dec 2021]

<http://www.nasonline.org/news-and-multimedia/>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 4 Dec 2021]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 4 Dec 2021]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

### **NIH Statement on World AIDS Day 2021**

December 1, 2021 — Statement of Anthony S. Fauci, M.D. and Maureen M. Goodenow, Ph.D.

... Although the HIV vaccine field has been marked by disappointing results over the years, finding a safe, effective and durable HIV vaccine remains an NIH priority. Currently, the Phase 3 Mosaico/HPTN 706 HIV vaccine clinical trial is underway in the Americas and Europe with results expected in 2024. Lessons learned from highly effective SARS-CoV-2 vaccines also offer an encouraging path forward for HIV vaccine discovery by providing applications for new vaccine platforms, such as mRNA, and novel strategies for rapidly identifying vaccine targets. Additionally, promising outcomes utilizing bNAbs suggest it may be possible to achieve an HIV vaccine with a high level of efficacy—an almost inconceivable scientific possibility several years ago...

### **Too many people with HIV fail to achieve durable viral suppression**

November 30, 2021 — NIH-funded study estimates global progress toward UNAIDS goal.

Article: WM Han et al. *Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries(link is external)*. The Lancet HIV (2021).

**OECD** [to 4 Dec 2021]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

*Newsroom*

### **Japan: broaden the digital transition to strengthen economic recovery from COVID-19, says OECD**

3-December-2021

Rising vaccination rates and a rebound in exports are helping Japan's economy to recover from the shock caused by COVID-19, although challenges remain. Investing in technology, education and professional training to broaden and accelerate the country's digital transformation would help to spur productivity growth and reinforce public finances, according to a new OECD report.

**PATH** [to 4 Dec 2021]

<https://www.path.org/media-center/>

*Press Releases*

### **PATH welcomes commitment by Gavi board to finance wider rollout of the world's first malaria vaccine, RTS,S**

December 2, 2021 by PATH

- Today's important decision enables low- and middle-income countries to consider adding RTS,S as an additional tool to combat malaria

- Additional investments will be needed to expand vaccine supply if current demand projections are realized
- Together with partners and other stakeholders, PATH is working to help ensure sufficient malaria vaccine supply to meet potential demand

**Sabin Vaccine Institute** [to 4 Dec 2021]  
<http://www.sabin.org/updates/pressreleases>  
*Statements and Press Releases*  
*No new digest content identified.*

**UNAIDS** [to 4 Dec 2021]  
<http://www.unaids.org/en>  
*Selected Press Releases/Reports/Statements*  
 3 December 2021  
[\*\*Strengthening Haiti's HIV response through community-led monitoring\*\*](#)

2 December 2021  
[\*\*Community health workers strengthen HIV and COVID-19 responses\*\*](#)

1 December 2021  
[\*\*Letter from Prince Harry to Dr Tedros Adhanom Ghebreyesus and Ms Winnie Byanyima on World AIDS Day\*\*](#)

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 4 Dec 2021]  
<http://www.unhcr.org/en-us/media-centre.html>  
*Selected News Releases, Announcements*  
[\*\*Prolonged COVID-19 pandemic deepens hardship for over 12 million forcibly displaced people with disabilities\*\*](#)  
 3 Dec 2021

At least 12 million people with disabilities are forcibly displaced worldwide, UNHCR, the UN Refugee Agency, estimates, and their already precarious situation is becoming harder as the COVID-19 pandemic drags on.

"Forced displacement disproportionately affects people with disabilities. They are often at higher risk of violence, discrimination, neglect, gender-based violence, exploitation and abuse, face barriers to access basic services, and are often excluded from education and livelihood opportunities," said Gillian Triggs, UNHCR's Assistant High Commissioner for Protection.

"While many refugees faced these unacceptable, pre-existing risks of exclusion and discrimination, we fear that the prolonged COVID-19 pandemic is only deepening inequalities and hardship," she added.

While estimates say over 12 million people with disabilities have been forcibly displaced by persecution, violence and human rights violations worldwide, surveys and assessments suggest the real number may be much higher.

Challenges and risks begin at the moment of flight. In sudden onset disasters, abrupt violence, and active hostilities, people with disabilities are often left behind by family members due to

the sudden nature of armed attacks; in extreme cases reported, people were abandoned while chained.

On reaching safety, services and facilities, including assistance programmes and protection, may be inaccessible. People with disabilities may face physical barriers and obstacles to reach, enter or use basic services, or key information may be delivered in formats not accessible to them.

Refugees and internally displaced and stateless people with disabilities were already less likely to access health care, education and employment opportunities, and the global crisis has further compounded this situation.

On the International Day of Persons with Disabilities today, UNHCR is urging national authorities to do more to secure the rights of forcibly displaced and stateless people with disabilities and to counter all forms of discrimination...

**UNICEF** [to 4 Dec 2021]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*Press release*

11/29/2021

**Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries**

**A joint statement from the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention (Africa CDC) and COVAX**

*[See Milestones above for detail]*

*Press release*

11/29/2021

**A child was infected with HIV every two minutes in 2020 – UNICEF**

A prolonged COVID-19 pandemic is deepening the inequalities that have long driven the HIV epidemic, UNICEF warns Ahead of World AIDS Day.

**Unitaid** [to 4 Dec 2021]

<https://unitaid.org/>

*Featured News*

30 November 2021

**COVID-19 creates new urgency for access to HIV self-testing, says global health agency Unitaid**

*The number of countries with self-testing policies in place has increased by nearly 15-fold since 2015, with an estimated 192 million self-tests needed to cover low- and middle-income countries by 2025.*

Geneva – Disruptions and delays to HIV services caused by the COVID-19 pandemic led to declines in HIV testing and diagnoses in 2020 for the first time in more than two decades. HIV self-testing, which has contributed to a 40% reduction in the number of people who do not know their HIV status since 2015, is now crucial to maintaining access to HIV care for millions of people in the face of new COVID-19 roadblocks.

With more than 37 million people living with HIV worldwide – an estimated 6.1 million of whom do not know their status – receiving a diagnosis is a vital first step in accessing treatment.

Unitaid has led a large-scale effort to create access to HIV treatment and prevention through self-testing, with more than US\$100 million invested since 2015. This work has helped reduce prices for self-tests, generate demand, demonstrate implementation pathways, and support scale up across 14

countries in Africa<sup>[1]</sup>, with more recent work in India and Indonesia looking to further expand successful self-testing strategies to more people...

While procurement of HIV self-tests is rising, it is greatly outpaced by the need. By 2025, the number of self-tests procured is projected to fill just 15% of the estimated 192 million tests needed in low- and middle-income countries. And although the funding allocated for self-testing has increased significantly over the past several years, an additional US\$104 million is needed to cover the costs of the 29 million self-tests expected to be procured.

Ahead of World AIDS Day, 1 December, Unitaid is calling for urgent funding and scale-up of HIV self-testing to protect progress threatened by COVID-19 and secure pathways to HIV treatment and prevention services for millions of people worldwide.

**Vaccine Equity Cooperative [nee Initiative]** [to 4 Dec 2021]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative (Sabin)** [to 4 Dec 2021]

<https://www.vaccineacceptance.org/>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 4 Dec 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 4 Dec 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 4 Dec 2021]

<https://wellcome.ac.uk/news>

*News, Opinion, Reports*

*News*

**“There isn't a united global strategy” – we need to ensure vaccine equity to end Covid-19**

30 November 2021

As the World Health Organization (WHO) announces a new variant of concern, we find out what people around the world think about Covid-19 vaccine distribution.

*News*

**Public trust in scientists rose during the Covid-19 pandemic**

29 November 2021

Insights from the [Wellcome Global Monitor](#) – the largest global survey of how people think and feel about science – found levels of trust in scientists have increased since 2018, placing it on par with doctors and nurses...

*Key findings*

[1] Covid-19 has put science in the public eye like never before. The Wellcome Global Monitor offers insight into how people think and feel about science and major health challenges worldwide.

Key findings include:

[2] The impact of Covid-19 has been uneven around the world. The Wellcome Global Monitor found that the pandemic has had a disproportionate impact on low-income countries and people with low incomes across all countries.

[3] People's trust in science and scientists has increased. Globally, those who said they trust scientists 'a lot' rose from 34% in 2018 to 43% by the end of 2020. These increases were highest among those who indicated they know 'some' or 'not much/nothing at all' about science.

People are not sure that their governments value scientific advice. World leaders need to listen and show that they share public confidence in the role of science in solving health challenges fairly for everyone.

**The Wistar Institute** [to 4 Dec 2021]

<https://www.wistar.org/news/press-releases>

*Press Releases*

Dec. 2, 2021

**[Fox Chase Cancer Center, The Wistar Institute Announce Opening of Phase 1 Clinical Trial of Anticancer Drug Candidate](#)**

PHILADELPHIA — (Dec. 2, 2021) — Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer. Gamitrinib is a first-in-class, mitochondrial-targeted inhibitor of the molecular chaperone heat shock protein-90 (HSP90) that works by inhibiting tumor cell metabolism and survival.

*Press Release*

Nov. 30, 2021

**[Wistar Scientists Identify Genes Critical to Protecting Ovarian Cancer from the Immune System](#)**

Discovery could make immunotherapy more effective for ovarian and other cancers.

**WFPHA: World Federation of Public Health Associations** [to 4 Dec 2021]

<https://www.wfpha.org/>

*Latest News - Blog*

**[A Vaccine TRIPS Waiver Now: Letter to WTO](#)**

Nov 29, 2021

Vaccination can save lives in millions. Massive upscaling of vaccine production is required across the globe with the COVID-19 pandemic continuing and with the prospect of new waves, and new variants in the future.

The World Federation of Public Health Associations, the Sustainable Health Equity Movement and the Global Network for Academic Public Health urge the World Trade Organisation to do everything in its power to achieve agreement to a temporary vaccine Trade-related Intellectual Property Rights waiver at its Ministerial Conference.

We believe the vaccine TRIPS waiver is the single most important action that can be taken to secure full and fair access to vaccine across the world, to give us the best possible chance of ending this pandemic, saving lives, and preventing disease and disability.

[Letter](#)

**World Bank** [to 4 Dec 2021]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

**[An Uneven Recovery: the Impact of COVID-19 on Latin America and the Caribbean](#)**

WASHINGTON D.C., November 29, 2021– Employment rates in some Latin American and Caribbean countries have experienced a relative recovery, although in most, rates fall short of pre-pandemic levels. The...

Date: November 29, 2021 Type: Press Release

**World Organisation for Animal Health (OIE)** [to 4 Dec 2021]

<https://www.oie.int/en/media/news/>

*Press Releases, Statements*

**[Tripartite and UNEP support OHHLEP's definition of "One Health"](#)**

*Joint Tripartite (FAO, OIE, WHO) and UNEP Statement*

*1 Dec 2021*

The Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), the United Nations Environment Programme (UNEP) and the World Health Organization (WHO) welcome the newly formed operational definition of One Health from their advisory panel, the One Health High Level Expert Panel (OHHLEP), whose members represent a broad range of disciplines in science and policy-related sectors relevant to One Health from around the world. The four organizations are working together to mainstream One Health so that they are better prepared to prevent, predict, detect, and respond to global health threats and promote sustainable development.

*The One Health definition developed by the OHHLEP states:*

**"One Health is an integrated, unifying approach that aims to sustainably balance and optimize the health of people, animals and ecosystems.** It recognizes the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and inter-dependent. The approach mobilizes multiple sectors, disciplines and communities at varying levels of society to work together to foster well-being and tackle threats to health and ecosystems, while addressing the collective need for clean water, energy and air, safe and nutritious food, taking action on climate change, and contributing to sustainable development."

**WTO - World Trade Organisation** [to 4 Dec 2021]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events*

**[Negotiations on services domestic regulation conclude successfully in Geneva](#)**

2 December 2021

Heads of Geneva delegations from the 67 WTO members participating in the Joint Initiative on Services Domestic Regulation announced on 2 December the successful conclusion of negotiations aimed at slashing administrative costs and creating a more transparent operating environment for



service providers hoping to do business in foreign markets.

### **DG calls on members to agree on pandemic response, fisheries subsidies by end-February**

2 December 2021

Following last week's eleventh-hour decision by WTO members to postpone the 12th Ministerial Conference, negotiations are continuing in Geneva, and Director-General Ngozi Okonjo-Iweala today (2 December) urged delegation heads to redouble their efforts to bridge differences. She called on them to conclude agreements on the WTO system's response to pandemics as well as on curbing harmful fisheries subsidies by the end of February 2022 to pave the way for approval by ministers. "Seven billion people are waiting for us on TRIPS and pandemic response. And 260 million people are waiting for us on fisheries subsidies," she said.

*[See Milestones above for detail]*

.....

### **ARM [Alliance for Regenerative Medicine]** [to 4 Dec 2021]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

### **BIO** [to 4 Dec 2021]

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

*No new digest content identified.*

### **DCVMN – Developing Country Vaccine Manufacturers Network** [to 4 Dec 2021]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

### **ICBA – International Council of Biotechnology Associations** [to 4 Dec 2021]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

### **IFPMA** [to 4 Dec 2021]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

### **Global pharmaceutical industry leaders meet with UK Prime Minister to discuss leadership in global health**

London, 3 December, 2021 – Yesterday, global leaders from the pharmaceutical industry met with the Prime Minister, senior UK Cabinet Ministers and the NHS Chief Executive, to discuss global health and innovation. Their discussions focused on how the industry and UK Government can work together

to drive pharmaceutical innovation and rapidly deliver the next generation of medicines to patients worldwide, and deliver on the ambition of the UK Government's Life Sciences Vision...

### **Global biopharmaceutical industry early response to Omicron**

3 December 2021 – COVID-19, the worst pandemic the world has seen in 100 years, has shown us that we cannot let our guard down. The global biopharmaceutical industry understands the concern caused by the emergence of the Omicron variant of COVID-19 since it was declared a variant of concern by the World Health Organization.

As a science-driven industry addressing some of the world's biggest healthcare challenges, the biopharmaceutical industry has demonstrated over the last two years how it is uniquely positioned to respond rapidly to COVID-19. Biopharmaceutical companies are bringing the same commitment to innovation in responding to the Omicron variant.

It is early days in terms of understanding Omicron. Together with the broader scientific community, public health and regulatory bodies around the world, our industry will again bring its experience and expertise to bear on new variants such as Omicron.

None of this work would have been possible if the South African and Botswana scientists had not shared the Omicron variant so swiftly through tried and tested platforms such as GISAID. Their fast sharing of the data has bought us all time in responding to and potentially controlling this new variant. The current situation reflects the advantage of fast and effective sharing of harmful pathogens and variants, which allows us to develop effective vaccines, treatments, and diagnostics.

Biopharmaceutical companies have hit the ground running in response to the Omicron variant, as they have done with previous variants (Beta and Delta). Crucially, they are looking at how both authorized and unapproved vaccines and treatments can stand up to this latest variant. A number of vaccine developers have already stated that they will develop Omicron targeting candidates.

The emergence of Omicron variant comes on top of a surge in COVID-19 cases in many regions of the world, caused by the dominant Delta variant at a time when health systems are already working hard to cope with seasonal endemic infections. Reducing the toll of the pandemic on lives and livelihoods requires not only continued innovation in the development and production of vaccines, treatments, and diagnostics, but also urgently addressing inequality in vaccine distribution and country readiness for vaccination. Our Five Steps to urgently advance COVID-19 vaccine equity announced in May 2022 are as relevant and as demanding of action today as they were when they were first launched.

### **Joint Statement on Patient Solidarity Day**

Geneva, December 3rd, 2021 – On Patient Solidarity Day, the International Alliance of Patients' Organizations (IAPO), the International Pharmaceutical Federation (FIP), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the International Hospital Federation (IHF) and the International Council of Nurses (ICN), join patients and families all over the world, in calling for governments and all health stakeholders to collaborate in the implementation of the WHO Flagship Global Patient Safety Action Plan 2021-2030 (GPSAP 2021-30) that was adopted at the 74th World Health Assembly this year.

Every year, large numbers of patients are harmed or die because of unsafe health care, creating a high burden of death and disability worldwide, especially in low- and middle-income countries. On average, an estimated one in 10 patients is subject to an adverse event while receiving hospital care in high-income countries. Available evidence suggests that 134 million adverse events due to unsafe care occur in hospitals in low- and middle-income countries, contributing to around 2.6 million deaths every year. According to recent estimates, the social cost of patient harm can be valued at US\$ 1 trillion to 2 trillion a year.<sup>[1]</sup>

Patient safety is fundamental to the provision of health care in all settings. However, avoidable adverse events, errors and risks associated with health care remain major challenges for patient safety globally. The global COVID-19 pandemic has highlighted the importance of building a culture of trust in healthcare systems, health professionals and medical products. Trust can be undermined by products and interventions that do not adhere to the highest standards of quality and ethical standards.

We therefore call on all governments and health stakeholders to deploy patient safety as a health priority in health sector policies and programmes to achieve universal health coverage; and for all health stakeholders to uphold the guiding principles of GPSAP 2021-30, by working to:

- Implement policies to eliminate avoidable harm in health
- Foster high-reliability systems
- Ensure safety of clinical processes
- Maintain patient and family engagement
- Secure continuous health worker education, skills and safety

Today, representing key actors in health systems, we reaffirm our commitment to provide the highest quality health care and health products to patients and to work towards the GPSAP 2021-30 vision of “a world in which no one is harmed in health care, and every patient receives safe and respectful care, every time, everywhere”.

*[1] Global Patient Safety Action Plan 2021–2030 Towards eliminating avoidable harm in health care*

### **Biopharmaceutical industry collaborates on the implementation of the G7 100 Days Mission to improve readiness**

Published on: 03 December 2021

The biopharmaceutical industry welcomes the publication of the [100 Days Mission – First Implementation Report](#) released on 2 December, which maps out key actions needed from all stakeholders to build global pandemic preparedness. As one of the implementation partners, we welcome the strong sense of public-private work involved to achieve this shared ambition is important and will be critical to future success.

The industry has played a full and integral role in tackling COVID-19 and we are committed to working with all partners – including the German G7 Presidency – to ensure the world is better prepared against future pandemics.

Following the World Health Assembly’s decision this week to launch a process to seek a global agreement on pandemic prevention, preparedness and response and we also support working with governments, international organizations and other stakeholders to make sure that policies and plans are developed in a way that achieves the effective response the world requires to tackle any future pandemic.

The 100 Day Mission roadmap indicates that it is well underway towards completion. It should provide useful insights for the global pandemic preparedness process that will be negotiated over the coming years. Both processes should recognise that emerging pathogens must be shared on or before Day 0 of future pandemics, and that any delays due to conditions applied to such sharing must be avoided if we are to achieve the 100 days objectives.

As a global community, we applaud the speed with which scientists are currently sharing pathogens. Their efforts should not be restricted by unclear legislation or unnecessary paperwork. From the very beginning of the pandemic the biopharmaceutical industry has worked in global partnerships with governments, health systems and across industry to deliver safe and effective COVID-19 vaccines and treatments.

We must now build on the successes of COVID-19, exploring new public-private partnerships to accelerate vaccine and drug discovery for priority pathogens and prepare for new pathogens.

COVID-19 has clearly demonstrated the importance of investment into R&D against future pathogens and COVID variants. These investments from across the R&D ecosystem – including large biopharmaceutical companies, small biotechs and academic researchers – is completely dependent on strong protection of intellectual property.

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

### **International Alliance of Patients' Organizations – IAPO** [to 4 Dec 2021]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

#### **Joint Statement On Patient Solidarity Day 2021**

London, December 3rd, 2021 - On Patient Solidarity Day, the International Alliance of Patients' Organizations (IAPO), the International Pharmaceutical Federation (FIP), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the International Hospital...

#### **Over 3000 patient advocates in Asia-Pacific come together calling for recovering together through compassion, insight and co-creation**

On 16 and 17 November 2021, 3800 patient advocates, government and policy makers, industry representatives, healthcare professionals, academia representatives, researchers and media came together for the virtual 3rd Asia-Pacific Patients Congress (APPC 2021) to share their vision and lived...

### **PhRMA** [to 4 Dec 2021]

<http://www.phrma.org/>

*Latest News [Selected]*

*No new digest content identified.*

\* \* \* \*

### **Contents [click to move among sections]**

:: [Milestones - Perspectives](#)

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

\* \* \* \*

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but

indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 23, Number 12: E905-1005 Dec 2021

<https://journalofethics.ama-assn.org/issue/health-care-and-homelessness>

#### ***Health Justice and Diversity in Medical School Admissions***

The Association of American Medical Colleges defines members of populations underrepresented in medicine "relative to their numbers in the general population." Diversity motivates key clinical and professional educational goals that can be sources of common ground when conflict emerges about which kinds of diversity should matter most and how applicants' memberships in minoritized groups should be regarded in admissions processes. Diversification and inclusion strategies vary in how effectively they motivate equity or retention among members of different groups in medicine, so how influential they should be is hotly contested and worthy of ethical investigation.

[No digest content identified]

### **American Journal of Infection Control**

December 2021 Volume 49 Issue 12 p1457-1578

<http://www.ajicjournal.org/current>

#### *Major Articles*

#### **[Impact of In-Hospital infection with SARS-CoV-2 among Inpatients at a university hospital](#)**

Josni Tauffer, Thais Claudia Roma de Oliveira Konstantyner, Maria Claudia Stockler de Almeida, ...

Suely Miyuki Yashiro, Antonia Maria de Oliveira Machado, Eduardo Alexandrino Medeiros

Published online: September 19, 2021

p1464-1468

#### *Brief Reports*

#### **[COVID-19 vaccination coverage among hospital-based healthcare personnel reported through the Department of Health and Human Services Unified Hospital Data Surveillance System, United States, January 20, 2021-September 15, 2021](#)**

Hannah E. Reses, Emma S. Jones, Donald B. Richardson, Kristopher M. Cate, David W. Walker, Craig N. Shapiro

Published online: November 17, 2021

p1554-1557

### **American Journal of Preventive Medicine**

December 2021 Volume 61 Issue 6 p771-928

<https://www.ajpmonline.org/current>

*Research Articles*

#### **Human Papillomavirus Vaccination and Human Papillomavirus–Associated Cancer Rates Within Florida Counties**

Stephanie A.S. Staras, Tianyao Huo, Sarah M. Rothbard,...Lindsay A. Thompson, Natalie L. Silver, Elizabeth A. Shenkman

Published online: August 09, 2021

p812-820

### **American Journal of Public Health**

November 2021 111(11)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 105 (2021): Issue 6 (Dec 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/6/tpmd.105.issue-6.xml>

Editorial

Open access

#### **Tropical Infectious Diseases: Still Here, Still Raging, Still Killing**

[Peter J. Hotez](#)

In our time of COVID-19, practically every public health agency—from local and state health departments, to the U.S. CDC, to the WHO—has concentrated its efforts on slowing SARS-2 coronavirus transmission. This occurred initially through nonpharmaceutical interventions and then, in the second year of the pandemic, through administering vaccinations. Despite these efforts, the consequences of the COVID-19 pandemic of 2019–2021 have been devastating. The most recent estimates from the Institute of Health Metrics and Evaluation at the University of Washington indicate that up to 6.5 million people will have lost their lives from COVID-19 by the end of 2021.<sup>1</sup>

Tragically, the deaths and disability-adjusted life years (DALYs) lost over this period will extend beyond the direct effects of SARS-2 coronavirus. For instance, in the United States and globally, the ensuing social disruptions slowed or even halted childhood vaccination programs.<sup>2,3</sup> Although childhood vaccinations are rebounding as waves of the COVID-19 epidemic pass, one worry is that all of the antivaccine aggression now directed at COVID-19 vaccines may spill over to other programs. In such a case, we might not achieve pre-pandemic immunization levels for many months or even years; we might experience resurgence of measles and other vaccine-preventable infectious diseases.<sup>4</sup>

Another concern is the diversion of global health programs toward COVID-19 at the expense of tropical infectious diseases such as the neglected tropical diseases (NTDs) and malaria. Since 2000, with the start of Millennium Development Goals programs, there have been enormous strides made in disease burden reductions for these conditions. For the NTDs, donor support from the governments of the United States and United Kingdom and operational research from the Bill & Melinda Gates Foundation, together with an ecosystem of nongovernmental development organizations (NGDOs), health ministries, and the WHO, have contributed to enormous reductions in the prevalence of NTDs through

mass drug administration and preventive treatments.<sup>5</sup> This is also true for global infection control programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria; the U.S. President's Emergency Plan for AIDS Relief and Malaria Initiative; as well as efforts to unify these programs under the banner of universal health coverage.<sup>6</sup>

Two new papers in the American Journal of Tropical Medicine and Hygiene (AJTMH) examine the consequences of the COVID-19 pandemic and its adverse impact on global efforts to control tropical infectious diseases in Africa.<sup>7,8</sup>...

#### *Perspective Pieces*

### **The Value and Interpretation of Race and Ethnicity Data in the Era of Global Migration: A Change Is in Order**

Serin Edwin Erayil, M. Kumi Smith, Tsige Gebreslasse, Patricia F. Walker, Erin M. Mann, Syreeta Wilkins, and William M. Stauffer

Volume/Issue: Volume 105: Issue 6

DOI: <https://doi.org/10.4269/ajtmh.21-0665>

Page(s): 1453–1455

### **Sex Workers Should Be Included in COVID-19 Vaccination Efforts**

Gladson Vaghela, Catherine Hermoso, Attaullah Ahmadi, and Don Eliseo Lucero-Prisno III

Volume/Issue: Volume 105: Issue 6

DOI: <https://doi.org/10.4269/ajtmh.21-0438>

#### *Articles*

### **Restarting Neglected Tropical Diseases Programs in West Africa during the COVID-19 Pandemic: Lessons Learned and Best Practices**

Achille Kabore, Stephanie L. Palmer, Ernest Mensah, Virginie Ettiegne-Traore, Rose Monteil, Franck Sintondji, Justin Tine, Daniel Tesfaye, Kisito Ogoussan, Diana Stukel, Brian B. Fuller, Katherine Sanchez, Bolivar Pou, Benoit Dembele, Angela Weaver, Steven Reid, Marie Denise Milord, Yao Kassankogno, Anders Seim, and Joseph Shott

Volume/Issue: Volume 105: Issue 6

DOI: <https://doi.org/10.4269/ajtmh.21-0408>

Page(s): 1476–1482

#### *Open access*

### **Relative Burdens of the COVID-19, Malaria, Tuberculosis, and HIV/AIDS Epidemics in Sub-Saharan Africa**

David Bell and Kristian Schultz Hansen

Volume/Issue: Volume 105: Issue 6

DOI: <https://doi.org/10.4269/ajtmh.21-0899>

Page(s): 1510–1515

### **Assessing Vaccine Coverage and Timeliness in Bamako, Mali after the Introduction of Rotavirus Vaccine: A Modified Immunization Cluster Survey**

Anna Roose, Uma Onwuchekwa, Milagritos Tapia, Samba Sow, T. Christopher Mast, and Karen Kotloff

Volume/Issue: Volume 105: Issue 6

DOI: <https://doi.org/10.4269/ajtmh.21-0148>

Page(s): 1594–1601



## **Annals of Internal Medicine**

November 2021 Volume 174, Issue 11

<http://annals.org/aim/issue>

[Reviewed earlier]

## **Artificial Intelligence – An International Journal**

Volume 301 December 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/301/suppl/C>

[New issue; No digest content identified]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 4 Dec 2021)

[No new digest content identified]

## **BMJ Global Health**

December 2021 - Volume 6 - 12

<https://gh.bmj.com/content/6/12>

*Commentary*

**[Build on HIV investments for future pandemic preparedness](#)** (3 December, 2021)

Chris Collins, Michael T Isbell, Jirair Ratevosian, Chris Beyrer, Quarraisha Abdool Karim, Allan Maleche, Annette H Sohn

*Original research*

**[Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis](#)** (2 December, 2021)

Seraphine Zeitouny, Katie J Suda, Kannop Mitsantisuk, Michael R Law, Mina Tadrous

**[Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries](#)** (2 December, 2021)

Sergio Torres-Rueda, Sedona Sweeney, Fiammetta Bozzani, Nichola R Naylor, Tim Baker, Carl Pearson, Rosalind Eggo, Simon R Procter, Nicholas Davies, Matthew Quaife, Nichola Kitson, Marcus R Keogh-Brown, Henning Tarp Jensen, Nuru Saadi, Mishal Khan, Maryam Huda, Angela Kairu, Raza Zaidi, Edwine Barasa, Mark Jit, Anna Vassall

**[The COVID-19 pandemic and healthcare systems in Africa: a scoping review of preparedness, impact and response](#)** (1 December, 2021)

Gizachew A Tessema, Yohannes Kinfu, Berihun Assefa Dachew, Azeb Gebresilassie Tesema, Yibeltal Assefa, Kefyalew Addis Alene, Atsedo Fantahun Aregay, Mohammed Biset Ayalew, Woldesellassie M Bezabhe, Ayele Geleto Bali, Abel Fekadu Dadi, Bereket Duko, Daniel Erku, Kahsu Gebrekidan, Kidane Tadesse Gebremariam, Lemlem Gebremedhin Gebremichael, Eyob Alemayehu Gebreyohannes, Yalemzewod Assefa Gelaw, Hailay Abrha Gesesew, Getiye Dejenu Kibret, Cheru Tesema Leshargie, Maereg Wagnew Meazew, Alemayehu Mekonnen, Alemnesh H. Mirkuzie, Hassen Mohammed, Dejen Yemane Tekle, Fisaha Haile Tesfay



## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 4 Dec 2021)

Research Open Access

### **The economic impact of compassionate use of medicines**

Authors: Claudio Jommi, Federico Pantellini, Lisa Stagi, Maria Verykiou and Marianna Cavazza

Citation: BMC Health Services Research 2021 21:1303

Content type: Research

Published on: 4 December 2021

### **Acceptability of mobile-phone reminders for routine childhood vaccination appointments in Nigeria – a systematic review and meta-analysis**

Mobile-phone reminders have gained traction among policymakers as a way to improve childhood vaccination coverage and timeliness. However, there is limited evidence on the acceptability of mobile-phone reminders...

Authors: Paul Eze, Sergius Alex Agu, Ujunwa Justina Agu and Yubraj Acharya

Citation: BMC Health Services Research 2021 21:1276

Content type: Research

Published on: 26 November 2021

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 4 Dec 2021)

### **Immune response to hepatitis B vaccine following complete immunization of children attending two regional hospitals in the Southwest region of Cameroon: a cross sectional study**

*Hepatitis B virus (HBV) infection despite being a vaccine preventable disease remains a global public health problem. In Cameroon, the hepatitis B vaccine was introduced in the expanded program on immunisation...*

Authors: Ephesians N. Anutebeh, Lambed Tatah, Vitalis F. Feteh, Desmond Aroke, Jules C. N. Assob and Simeon Pierre Choukem

Citation: BMC Infectious Diseases 2021 21:1205

Content type: Research

Published on: 2 December 2021

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 4 Dec 2021)

### **Making complex decisions in uncertain times: experiences of Dutch GPs as gatekeepers regarding hospital referrals during COVID-19—a qualitative study**

*General practitioners often act as gatekeeper, authorizing patients' access to hospital care. This gatekeeping role became even more important during the current COVID-19 crisis as uncertainties regarding COVID-19...*

Authors: Dieke Westerduin, Janneke Dujardin, Jaap Schuurmans, Yvonne Engels and Anne B. Wichmann

Citation: BMC Medical Ethics 2021 22:158

Content type: Research

Published on: 30 November 2021

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 4 Dec 2021)

### **Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review**

*How best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally. We reviewed epidemiological and economic modelling evidence...*

Authors: Nuru Saadi, Y-Ling Chi, Srobana Ghosh, Rosalind M. Eggo, Ciara V. McCarthy, Matthew Quaife, Jeanette Dawa, Mark Jit and Anna Vassall

Citation: BMC Medicine 2021 19:318

Content type: Review

Published on: 1 December 2021

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 4 Dec 2021)

### **Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysis**

*There is dearth of information on COVID-19's impact on pregnant women. However, literature reported trends of COVID-19 differ, depending on the presence of clinical features upon presentation.*

Authors: Durray Shahwar A. Khan, La-Raib Hamid, Anna Ali, Rehana A. Salam, Nadeem Zuberi, Zohra S. Lassi and Jai K. Das

Citation: BMC Pregnancy and Childbirth 2021 21:801

Content type: Research

Published on: 1 December 2021

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 4 Dec 2021)

### **Vaccination in pregnancy against pertussis and seasonal influenza: key learnings and components from high-performing vaccine programmes in three countries: the United Kingdom, the United States and Spain**

*Pertussis and seasonal influenza are responsible for significant maternal, neonatal, and infant morbidity and mortality, but vaccine coverage rates (VCR) for both pertussis (administered as a tetanus, diphther...*

Authors: Théophile Baïssas, Florence Boissard, Inmaculada Cuesta Esteve, Marta Garcia Sánchez, Christine E. Jones, Thierry Rigoine de Fougerolles, Litjen Tan, Olivier Vitoux and Christina Klein

Citation: BMC Public Health 2021 21:2182

Content type: Research

Published on: 29 November 2021

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 4 Dec 2021)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

December 2021 - Volume 26 - 6

<https://ebm.bmj.com/content/26/6>

[Reviewed earlier]

### **BMJ Open**

December 2021 - Volume 11 - 12

<https://bmjopen.bmj.com/content/11/12>

**[Original research: Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review](#)** (2 December, 2021)

Mari Somerville, Janet A Curran, Justine Dol, Leah Boulos, Lynora Saxinger, Alexander Doroshenko, Stephanie Hastings, Bearach Reynolds, Allyson J Gallant, Hwayeon Danielle Shin, Helen Wong, Daniel Crowther, Marilyn Macdonald, Ruth Martin-Misener, Jeannette Comeau, Holly McCulloch, Andrea C Tricco

### **Bulletin of the World Health Organization**

Volume 99(12); 2021 Dec 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/394921/>

*Editorials*

### **[Optimizing the supply of vaccines for COVID-19](#)**

Angela K Shen, Ann Lindstrand, Benjamin Schreiber, Kate O'Brien

Bull World Health Organ. 2021 Dec 1; 99(12): 848–848A. Published online 2021 Dec 1.

doi: 10.2471/BLT.21.287513

PMCID: PMC8640687

The global health community and the COVID-19 Vaccine Global Access (COVAX) initiative – the partnership co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, the World Health Organization (WHO) and the United Nations' Children's Fund (UNICEF) – have focused on securing vaccines for the coronavirus disease 2019 (COVID-19) to equitably vaccinate the world's population. Besides the complex task of securing and distributing billions of doses for vaccination programmes, country readiness to administer these doses is a daunting challenge. Vaccination requires more than just vaccines.

UNICEF, WHO and Gavi have established a COVID-19 vaccination Country Readiness and Delivery<sup>1</sup> workstream to support country readiness for COVID-19 vaccination programmes as part of COVAX...

## *Perspectives*

### **Towards a universal understanding of post COVID-19 condition**

Janet V Diaz, Margaret Herridge, Silvia Bertagnolio, Hannah E Davis, Tarun Dua, Charu Kaushic, John C Marshall, Maria del Rosario Pérez, Nathalie Strub-Wourgaft, Joan B Soriano

Bull World Health Organ. 2021 Dec 1; 99(12): 901–903. Published online 2021 Oct 5.

doi: 10.2471/BLT.21.286249

PMCID: PMC8640686

### **Establishing consensus on ethics, traceability and biovigilance for medical products of human origin**

Paul Ashford, Jeremy Chapman, Martin Hildebrandt, Luc Noël, Timothy Pruett, Ineke Slaper-Cortenbach, Diane Wilson

Bull World Health Organ. 2021 Dec 1; 99(12): 907–909. Published online 2021 Oct 28.

doi: 10.2471/BLT.21.285484

PMCID: PMC8640690

### **Addressing production gaps for vaccines in African countries**

Anna Mia Ekström, Göran Tomson, Rhoda K Wanyenze, Zulfiqar A Bhutta, Catherine Kyobutungi, Agnes Binagwaho, Ole Petter Ottersen

Bull World Health Organ. 2021 Dec 1; 99(12): 910–912. Published online 2021 Nov 17.

doi: 10.2471/BLT.21.287381

PMCID: PMC8640685

## **Cell**

Nov 24, 2021 Volume 184 Issue 24 p5839-6006

<https://www.cell.com/cell/current>

[Reviewed earlier]

## **Child Care, Health and Development**

Volume 47, Issue 6 Pages: 733-885 November 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

## **Clinical Pharmacology & Therapeutics**

Volume 110, Issue 6 Pages: 1403-1633 December 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New issue; No digest content identified]

## **Clinical Therapeutics**

October 2021 Volume 43 Issue 10 p1627-1808

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 18 Issue 6, December 2021

<https://journals.sagepub.com/toc/ctja/18/6>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 4 Dec 2021]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 110 November 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/110/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 4, Issue 5 / October 2021

<https://www.liebertpub.com/toc/crispr/4/5>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

December 2021 - Volume 34 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

**Developing World Bioethics**

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

*COUNTRY REPORTS*

*Free Access*

**A fair allocation approach to the ethics of scarce resources in the context of a pandemic:  
The need to prioritize the worst-off in the Philippines**

Leonardo De Castro, Alexander Atrio Lopez, Geohari Hamoy, Kriedge Chlare Alba, Joshua Cedric Gundayao

Pages: 153-172

First Published: 23 September 2020

*Free Access*

**Seeking an ethical theory for the COVID-19 pandemic outbreak with special reference to Bangladesh's law and policy**

A S M Anwarullah Bhuiyan

Pages: 173-186

First Published: 06 September 2020

**Development in Practice**

Volume 31, Issue 8, 2021

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 45, Issue 4 Pages: 739-995 October 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**EMBO Reports**

Volume 22 Issue 11 4 November 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

**Emerging Infectious Diseases**

Volume 27, Number 11—November 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

**Epidemics**

Volume 36 September 2021

<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 43, Issue 6 Pages: 1-48 November–December 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

### **Ethics & International Affairs**

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 19 December 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/19/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 31, Issue Supplement\_4, November 2021 *Supplement*

<https://academic.oup.com/eurpub/issue/31/5>

#### ***COVID-19: What have we learned? What are the public health challenges?***

Guest Editors: Dineke Zeegers Paget, Iveta Nagyova, Peter Allebeck

*Supplement papers*

#### **[COVID-19: What have we learned? What are the public health challenges?](#)**

Dineke Zeegers Paget, Peter Allebeck, Iveta Nagyova

European Journal of Public Health, Volume 31, Issue Supplement\_4, November 2021, Pages iv1–iv2,

<https://doi.org/10.1093/eurpub/ckab150>

#### **[Research into policy: lessons from the COVID-19 pandemic](#)**

May C I van Schalkwyk, Martin McKee

European Journal of Public Health, Volume 31, Issue Supplement\_4, November 2021, Pages iv3–iv8,  
<https://doi.org/10.1093/eurpub/ckab155>

**[Reducing the impact of the coronavirus on disadvantaged migrants and ethnic minorities](#)**

Bernadette N Kumar, Sally Hargreaves, Charles Agyemang, Rosemary A James, Karl Blanchet ...  
European Journal of Public Health, Volume 31, Issue Supplement\_4, November 2021, Pages iv9–iv13,  
<https://doi.org/10.1093/eurpub/ckab151>

**[Ethical implications of COVID-19: vulnerabilities in a global perspective](#)**

Els Maeckelberghe  
European Journal of Public Health, Volume 31, Issue Supplement\_4, November 2021, Pages iv50–iv53,  
<https://doi.org/10.1093/eurpub/ckab158>

**[The accountability of the private sector towards citizens in times of crisis: vaccines, medicines and equipment](#)**

Elena Petelos, Dimitra Lingri, Jinane Ghattas, Silvia M A A Evers, Dineke Zeegers Paget ...  
European Journal of Public Health, Volume 31, Issue Supplement\_4, November 2021, Pages iv54–iv58,  
<https://doi.org/10.1093/eurpub/ckab160>

**Expert Review of Vaccines**

Vol 20 (10) 2021  
<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

**Forum for Development Studies**

Volume 48, 2021 - Issue 3  
<http://www.tandfonline.com/toc/sfds20/current>  
[Reviewed earlier]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>  
[Accessed 4 Dec 2021]  
[No new digest content identified]

**Global Health Action**

Volume 14, Issue 1 (2021)  
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>  
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

Vol. 9, No. 3 September 30, 2021  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]



**Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 4 Dec 2021]

[No new digest content identified]

**Global Public Health**

Volume 16, Issue 12 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 4 Dec 2021]

[No new digest content identified]

**Health and Human Rights**

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

[Reviewed earlier]

**Health Economics, Policy and Law**

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

**Health Policy and Planning**

Volume 36, Issue 10, December 2021

<https://academic.oup.com/heapol/issue/36/10>

[New issue; No digest content identified]

**Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 4 Dec 2021]

[No new digest content identified]

**Human Gene Therapy**

Volume 32, Issue 21-22 / November 2021

<https://www.liebertpub.com/toc/hum/32/21-22>

[New issue; No digest content identified]

## **Humanitarian Exchange Magazine**

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

### **Localisation and local humanitarian action**

*by HPN October 2020*

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

## **Immunity**

Nov 09, 2021 Volume 54 Issue 11 p2437-2670

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 4 Dec 2021]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 4 Dec 2021]

[No new digest content identified]

## **International Health**

Volume 13, Issue 6, November 2021

<https://academic.oup.com/inthealth/issue/13/6>

*RSTMH STUDENT ESSAY PRIZE*

**[COVID-19 in an inequitable world: the last, the lost and the least](#)**

Mark K I Tan

International Health, Volume 13, Issue 6, November 2021, Pages 493–496,

<https://doi.org/10.1093/inthealth/ihab057>

*ORIGINAL ARTICLES*

**[‘When you welcome well, you vaccinate well’: a qualitative study on improving vaccination coverage in urban settings in Conakry, Republic of Guinea](#)**

Julita Gil Cuesta, Katherine Whitehouse, Salimou Kaba, Kassi Nanan-N’Zeth, Benoit Haba ...

International Health, Volume 13, Issue 6, November 2021, Pages 586–593,

<https://doi.org/10.1093/inthealth/ihz097>

*COMMENTARY*

**[Taking stock of global immunisation coverage progress: the gains, the losses and the journey ahead](#)**

C A Nnaji, A J Owoyemi, U A Amaechi, A B Wiyeh, D E Ndwandwe ...

International Health, Volume 13, Issue 6, November 2021, Pages 653–657,

<https://doi.org/10.1093/inthealth/ihz120>

**International Human Rights Law Review**

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 8, No 10 (2021) October 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 50, Issue 5, October 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 14 Issue 5 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>

*Table of Contents*

[New issue; No digest content identified]

**International Journal of Infectious Diseases**

December 2021 Volume 113 p1-366

<https://www.ijidonline.com/current>

*Coronavirus (COVID-19) Collection*

**[Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers](#)**

Theodore W. Heyming, Diane Nugent, Aprille Tongol,...Kellie Bacon, Bryan Lara, Terence Sanger

Published online: September 30, 2021

p1-6

**[The Global Health Security Index is not predictive of vaccine rollout responses among OECD countries](#)**

Banda A. Khalifa, Enoch J. Abbey, Samuel K. Ayeh,...Emmanuella L. Salia, Oluwatobi Lasisi, Petros C. Karakousis

Published online: September 18, 2021

**[Measuring the impact of a single dose of ChAdOx1 nCoV-19 \(recombinant\) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre](#)**

Anuja Desai, Parth Desai, Jigar Mehta,...Vivek Nanda, Parin Mehta, Adit Desai

Published online: October 20, 2021

p282-287

**JAMA**

November 23/30, 2021, Vol 326, No. 20, Pages 1995-2087

<https://jamanetwork.com/journals/jama/currentissue>

[Reviewed earlier]

**JAMA Network**

**[COVID-19 Update December 4, 2021](#)**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

**JAMA Pediatrics**

November 2021, Vol 175, No. 11, Pages 1093-1192

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

**JBI Evidence Synthesis**

November 2021 - Volume 19 - Issue 11

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

**Journal of Adolescent Health**

December 2021 Volume 69 Issue 6 p861-1054

<https://www.jahonline.org/current>

*Commentaries*

**How Can We Best Use COVID-19 Vaccines in Adolescents? An International Perspective**

Youjia Zhong, Le Ye Lee, Paul Ananth Tambyah, Woei Kang Liew, Bee Wah Lee

Published in issue: December 2021

p878-880

**How Can We Best Use COVID-19 Vaccines in Adolescents? A Perspective From the United States**

Donna L. Tyungu, Sean T. O'Leary, Amy B. Middleman

Published online: September 22, 2021

p881-883

**COVID-19 Vaccines for Adolescents: Leveraging the ABCs of Communication**

Beth L. Hoffman, Todd Wolynn, Jaime E. Sidani

Published online: October 14, 2021

p884-885

*Original Articles*

**Parent and Peer Norms are Unique Correlates of COVID-19 Vaccine Intentions in a Diverse Sample of U.S. Adolescents**

Adam A. Rogers, Rachel E. Cook, Julie A. Button

Published online: September 22, 2021

p910-916

*Adolescent Health Briefs*

**COVID-19 Vaccine Sentiments Among African American or Black Adolescents in Rural Alabama**

Henna Budhwani, Tiffani Maycock, Wilnadia Murrell, Tina Simpson

Published online: September 24, 2021

**Journal of Artificial Intelligence Research**

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 46, issue 6, December 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-6>

*Original Paper*

**COVID-19 Vaccination and Intention to Vaccinate Among a Sample of College Students in New Jersey**

Authors (first, second and last of 5)

Aleksandar Kecojovic, Corey H. Basch, Nicole K. Davi

Published: 27 April 2021

Pages: 1059 - 1068

**COVID-19 Vaccine Hesitancy and Its Determinants Among Adults with a History of Tobacco or Marijuana Use**

Authors Yong Yang, Aram Dobalian, Kenneth D. Ward

Content type: Original Paper

Published: 06 May 2021

Pages: 1090 - 1098

**Primary Care Interventions to Address COVID-19 Vaccine Hesitancy Among Israel Defense Forces Soldiers**

Authors (first, second and last of 4) Tomer Talmy, Bar Cohen, Yossi Ben Michael

Content type: Original Paper

Published: 14 May 2021

Pages: 1155 - 1160

**Knowledge and Attitudes Toward Covid-19 and Vaccines Among a New York Haredi-Orthodox Jewish Community**

Authors (first, second and last of 5) Ellie R. Carmody, Devon Zander, Arthur L. Caplan

Content type: Original Paper

Published: 17 May 2021

Pages: 1161 - 1169

**Human Papillomavirus Vaccination and Pap Smear Rates Among Burmese Refugee Girls in a Healthcare System in Omaha, Nebraska**

Authors (first, second and last of 4) Dorothy Xuanxian Kenny, Katherine Hsueh, John Joseph Côté

Content type: Original Paper

Published: 21 May 2021

Pages: 1170 - 1176

**The Nature and Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers**

Authors (first, second and last of 4) Nirbachita Biswas, Toheeb Mustapha, James H. Price

Content type: Review

Published: 20 April 2021

Pages: 1244 - 1251

**Journal of Development Economics**

Volume 153 November 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/153/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 16 Issue 5, December 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

November 2021 - Volume 75 - 11  
<https://jech.bmj.com/content/75/11>  
[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 14, Issue 3 Pages: 171-256 September 2021  
<https://onlinelibrary.wiley.com/toc/17565391/current>  
[Reviewed earlier]

**Journal of Global Ethics**

Volume 17, Issue 1, 2021  
<http://www.tandfonline.com/toc/rjge20/current>  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 32, Number 4, November 2021  
<https://muse.jhu.edu/issue/46802>

*Table of Contents*

Commentaries

**[Cholera: Still a Major Public Health Issue in Sub-Saharan Africa](#)**

Merlyn Dorsainvil

pp. 1734-1741

DOI: [10.1353/hpu.2021.0162](https://doi.org/10.1353/hpu.2021.0162)

**[Aftermath of COVID-19: Forestalling Irreparable Medical Brain Drain in Sub-Saharan Africa](#)**

Justus Uchenna Onu, Sunday O Oriji, Deborah Oyine Aluh, Tonia C Onyeka

pp. 1742-1751

DOI: [10.1353/hpu.2021.0163](https://doi.org/10.1353/hpu.2021.0163)

**Journal of Immigrant and Minority Health**

Volume 23, issue 6, December 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-6>

[New issue; No digest content identified]

**Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

**Journal of Medical Ethics**

December 2021 - Volume 47 - 12

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

**Journal of Patient-Centered Research and Reviews**

Volume 8, Issue 4 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

***Cancer Screening***

[Reviewed earlier]

**Journal of Pediatrics**

November 2021 Volume 238 p1-348

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 4 Dec 2021]

[No new digest content identified]

**Journal of Public Health Management & Practice**

November/December 2021 - Volume 27 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 42, issue 3, September 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-3>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

December 2021 Volume 18 Issue 185



<https://royalsocietypublishing.org/toc/rsif/current>  
[New issue; No digest content identified]

### **Journal of Travel Medicine**

Volume 28, Issue 7, October 2021  
<https://academic.oup.com/jtm/issue>  
[Reviewed earlier]

### **Journal of Virology**

Volume 95 Number 24 November 2021  
<http://jvi.asm.org/content/current>  
[New issue; No digest content identified]

### **The Lancet**

Dec 04, 2021 Volume 398 Number 10316 p2051-2124  
<https://www.thelancet.com/journals/lancet/issue/current>  
*Editorial*

#### **[Reinstating universal health coverage on the global agenda](#)**

The Lancet

#### *Comment*

#### **[Cervical cancers avoided by HPV immunisation](#)**

Maggie E Cruickshank, Mihaela Grigore

#### *Articles*

#### **[The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study](#)**

Milena Falcaro, et al.

#### **[Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study](#)**

Noam Barda, et al.

#### *Health Policy*

#### **[How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic](#)**

Sudhvir Singh, et al.

Published: November 08, 2021

#### *Summary*

Understanding the spread of SARS-CoV-2, how and when evidence emerged, and the timing of local, national, regional, and global responses is essential to establish how an outbreak became a pandemic and to prepare for future health threats. With that aim, the Independent Panel for Pandemic Preparedness and Response has developed a chronology of events, actions, and recommendations, from December, 2019, when the first cases of COVID-19 were identified in China, to the end of March,

2020, by which time the outbreak had spread extensively worldwide and had been characterised as a pandemic. Datapoints are based on two literature reviews, WHO documents and correspondence, submissions to the Panel, and an expert verification process. The retrospective analysis of the chronology shows a dedicated initial response by WHO and some national governments, but also aspects of the response that could have been quicker, including outbreak notifications under the International Health Regulations (IHR), presumption and confirmation of human-to-human transmission of SARS-CoV-2, declaration of a Public Health Emergency of International Concern, and, most importantly, the public health response of many national governments. The chronology also shows that some countries, largely those with previous experience with similar outbreaks, reacted quickly, even ahead of WHO alerts, and were more successful in initially containing the virus. Mapping actions against IHR obligations, the chronology shows where efficiency and accountability could be improved at local, national, and international levels to more quickly alert and contain health threats in the future. In particular, these improvements include necessary reforms to international law and governance for pandemic preparedness and response, including the IHR and a potential framework convention on pandemic preparedness and response.

### **The Lancet Child & Adolescent Health**

Dec 2021 Volume 5 Number 12 p837-904, e44-e46

<https://www.thelancet.com/journals/lanchi/issue/current>

*Comment*

#### **Eliminating malaria in southeast Asia requires more attention on adolescent girls**

Abena Poku-Awuku, et al.

### **Lancet Digital Health**

Dec 2021 Volume 3 Number 12 e751-e829

<https://www.thelancet.com/journals/landig/issue/current>

*Review*

#### **Blockchain applications in health care for COVID-19 and beyond: a systematic review**

Wei Yan Ng, et al.

*Summary*

The COVID-19 pandemic has had a substantial and global impact on health care, and has greatly accelerated the adoption of digital technology. One of these emerging digital technologies, blockchain, has unique characteristics (eg, immutability, decentralisation, and transparency) that can be useful in multiple domains (eg, management of electronic medical records and access rights, and mobile health). We conducted a systematic review of COVID-19-related and non-COVID-19-related applications of blockchain in health care. We identified relevant reports published in MEDLINE, SpringerLink, Institute of Electrical and Electronics Engineers Xplore, ScienceDirect, arXiv, and Google Scholar up to July 29, 2021. Articles that included both clinical and technical designs, with or without prototype development, were included. A total of 85 375 articles were evaluated, with 415 full length reports (37 related to COVID-19 and 378 not related to COVID-19) eventually included in the final analysis. The main COVID-19-related applications reported were pandemic control and surveillance, immunity or vaccine passport monitoring, and contact tracing. The top three non-COVID-19-related applications were management of electronic medical records, internet of things (eg, remote monitoring or mobile health), and supply chain monitoring. Most reports detailed technical performance of the blockchain prototype platforms (277 [66·7%] of 415), whereas nine (2·2%) studies showed real-world clinical application and adoption. The remaining studies (129 [31·1%] of 415) were themselves of a technical design only. The

most common platforms used were Ethereum and Hyperledger. Blockchain technology has numerous potential COVID-19-related and non-COVID-19-related applications in health care. However, much of the current research remains at the technical stage, with few providing actual clinical applications, highlighting the need to translate foundational blockchain technology into clinical use.

## **Lancet Global Health**

Dec 2021 Volume 9 Number 12 e1623-e1769

<https://www.thelancet.com/journals/langlo/issue/current>

*Editorial*

### **[A bright future in typhoid vaccines](#)**

The Lancet Global Health

*Comment*

### **[Reaching zero-dose children in India: progress and challenges ahead](#)**

Manoj V Murhekar, Muthusamy, Santhosh Kumar

### **[Navigating the violent process of decolonisation in global health research: a guideline](#)**

Muneera A Rasheed

### **[Ethical considerations for introducing RTS,S/AS01 in countries with moderate to high Plasmodium falciparum malaria transmission](#)**

Jeff D'Souza, David Nderitu

*Articles*

### **[Genomic epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely collected surveillance data](#)**

Tapfumanei Mashe, et al. on behalf of the COVID-19 Genomics UK Consortium, and the SARS-CoV-2 Research Group

*Articles*

### **[Progress in reaching unvaccinated \(zero-dose\) children in India, 1992–2016: a multilevel, geospatial analysis of repeated cross-sectional surveys](#)**

Mira Johri, Sunil Rajpal, S V Subramanian

*Summary*

**Background**

Reaching zero-dose children (infants who receive no routine vaccinations) is a global strategic priority. We studied zero-dose children in India over 24 years to clarify aggregate trends and the contribution of large-scale social, economic, and geographical inequalities to these.

**Methods**

We did a multilevel, geospatial analysis of repeated cross-sectional surveys of all four rounds (1992–2016) of India's National Family Health Survey to study the prevalence, distribution, and drivers of zero-dose (no first dose of diphtheria, tetanus, and pertussis) vaccination status. We included all children born to participating women who were aged 12–23 months at the time of the survey, as this is the standard age at which immunisation data are assessed. Children who died before the survey and those missing data on key outcomes or correlates were excluded. The outcome was child zero-dose vaccination status. We also compared the prevalence of nutritional deficits among zero-dose versus

vaccinated children. For the most recent survey, we produced geospatial estimates identifying the prevalence of zero-dose children across states and districts and used these to project head count.

#### Findings

We examined 393 167 children for eligibility. 72 848 children were included in the final analytic data set. The proportion of zero-dose children in India declined from 33·4% (95% CI 32·5–34·2) in 1992 to 10·1% (9·8–10·4) in 2016. Progress notwithstanding, in 2016, zero-dose children remained concentrated among disadvantaged groups (prevalence in the bottom wealth quintile 15·3%, 95% CI 14·6–16·0; prevalence among mothers with no education 16·8%, 16·1–17·4). Compared with vaccinated children, zero-dose children were more likely to suffer from malnutrition in all survey rounds (prevalence of severe stunting in 1992: zero dose 41·3%, 95% CI 39·2–43·8 vs vaccinated 28·5%, 27·2–29·7; 2016: zero dose 24·9%, 23·6–26·2 vs vaccinated 18·7%, 18·3–19·1). In 2016, there were an estimated 2·88 (95% CI 2·86–2·89) million zero-dose children in India, concentrated in less developed states and districts and several urban areas.

#### Interpretation

Over a 24-year period in India, child zero-dose status was shaped by large-scale social inequalities and remained a consistent marker of generalised vulnerability. Interventions that address this cycle of intergenerational inequities should be prioritised.

### **Lancet Infectious Diseases**

Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406

<https://www.thelancet.com/journals/laninf/issue/current>

#### *Comment*

#### **[COVID-19 vaccines for children younger than 12 years: are we ready?](#)**

Xiaohui Zou, Bin Cao

#### *Articles*

#### **[Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine \(CoronaVac\) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial](#)**

Bihua Han, et al.

#### **[Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine \(Ad5-nCoV\) in adults: preliminary report of an open-label and randomised phase 1 clinical trial](#)**

Shipo Wu, et al.

#### **[Vaccination of human participants with attenuated \*Necator americanus\* hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial](#)**

Paul R Chapman, et al.

#### *Review*

#### **[Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review](#)**

Anna Deal, et al. in collaboration with the European Society of Clinical Microbiology and Infectious Diseases Study Group for Infections in Travellers and Migrants (ESGITM)

#### *Grand Round*

**Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis**

Umang Arora, et al.

**Lancet Public Health**

Dec 2021 Volume 6 Number 12 e866-e969

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

**Lancet Respiratory Medicine**

Dec 2021 Volume 9 Number 12 p1343-1478, e110-e122

<https://www.thelancet.com/journals/lanres/issue/current>

*Articles*

**Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan**

Szu-Min Hsieh, et al.

**COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study**

Utkarsh Agrawal, et al.

*Personal View*

**Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?**

Gregory Milne, et al.

**Maternal and Child Health Journal**

Volume 25, issue 12, December 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-12>

[New issue; No digest content identified]

**Medical Decision Making (MDM)**

Volume 42 Issue 1, January 2022

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 99, Issue 3 Pages: 601-852 September 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Nature**

Volume 600 Issue 7887, 2 December 2021

<https://www.nature.com/nature/volumes/600/issues/7887>

[New issue; No digest content identified]

## **Nature Biotechnology**

Volume 39 Issue 11, November 2021

<https://www.nature.com/nbt/volumes/39/issues/11>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 4 Dec 2021)

[No new digest content identified]

## **Nature Genetics**

Volume 53 Issue 11, November 2021

<https://www.nature.com/ng/volumes/53/issues/11>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 5 Issue 11, November 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/11>

[Reviewed earlier]

## **Nature Medicine**

Volume 27 Issue 11, November 2021

<https://www.nature.com/nm/volumes/27/issues/11>

### ***Diversity, Equity and Inclusion in medical research***

In this issue, Nature Medicine is launching a Series on Diversity, Equity and Inclusion in medical research. The first installment brings a perspective on the role of funders in addressing the continued lack of diversity in science and medicine in the United States, and an overview of how governmental, societal and philanthropic stakeholders are approaching lack of diversity and inequalities in their research programs.

[Reviewed earlier]

## **Nature Reviews Genetics**

Volume 22 Issue 12, December 2021

<https://www.nature.com/nrg/volumes/22/issues/12>

*Review Article* | 17 September 2021

[\*\*The biological and clinical significance of emerging SARS-CoV-2 variants\*\*](#)

In this Review, the authors describe our latest understanding of the emergence and properties of SARS-CoV-2 genetic variants, particularly those designated as WHO (World Health Organization) 'variants of concern'. They focus on the consequences of these variants for antibody-mediated virus neutralization, with important implications for reinfection risk and for vaccine effectiveness.  
Kaiming Tao, Philip L. Tzou, Robert W. Shafer

## **Nature Reviews Immunology**

Volume 21 Issue 12, December 2021

<https://www.nature.com/nri/volumes/21/issues/12>

*Comment* | 18 October 2021

### **Lessons from vaccine-induced immune thrombotic thrombocytopenia**

Here, John Kelton and colleagues provide an overview of vaccine-induced immune thrombotic thrombocytopenia (VITT), a very rare complication that has been observed following vaccination with adenoviral vector-based COVID-19 vaccines.

John Greenhow Kelton, Donald Mitchell Arnold, Ishac Nazy

*Progress* | 19 October 2021

### **The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?**

Individuals with asymptomatic COVID-19 can transmit the virus and may be at risk of long-term disease. In this Progress article, Boyton and Altman present current insights into immune responses in asymptomatic SARS-CoV-2 infection and discuss the relevance of asymptomatic disease for public health strategies.

Rosemary J. Boyton, Daniel M. Altmann

*Perspective* | 17 June 2021

### **Using cross-species vaccination approaches to counter emerging infectious diseases**

Emerging diseases that affect humans often arise due to the crossover of infectious agents from animal reservoirs. In this Perspective, George Warimwe and colleagues discuss the concept of 'One Health vaccinology', an approach that aims to use key lessons from human and veterinary immunology to develop more effective vaccination strategies for emerging infectious diseases.

George M. Warimwe, Michael J. Francis, Bryan Charleston

*Perspective* | 25 October 2021

### **Lessons from the elimination of poliomyelitis in Africa**

This Perspective chronicles the journey to the elimination of transmission of wild poliovirus in Africa, with a critical discussion of the global, continental, national and community actions that were required and the lessons learnt along the way.

Abdulaziz Mohammed, Oyewale Tomori, John N. Nkengasong

## **Nature Reviews Drug Discovery**

Volume 20 Issue 12, December 2021

<https://www.nature.com/nrd/volumes/20/issues/12>

*Review Article* | 06 October 2021

### **Engineering living therapeutics with synthetic biology**

The design of cell-based therapeutics with synthetic biology is a rapidly growing strategy in medicine for the development of effective treatments for a variety of diseases. This article discusses advances in

synthetic biology approaches to programme living cells with therapeutic functions as well as challenges for their development.

Andres Cubillos-Ruiz, Tingxi Guo, Jose M. Lora

### **New England Journal of Medicine**

December 2, 2021 Vol. 385 No. 23

<http://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

#### **Myocarditis after Covid-19 Vaccination in a Large Health Care Organization**

G. Witberg and Others

#### **Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel**

D. Mevorach and Others

*Editorials*

#### **Receipt of mRNA Vaccine against Covid-19 and Myocarditis**

A.L.P. Caforio

#### **Audio Interview: The Omicron Variant of SARS-CoV-2**

E.J. Rubin, L.R. Baden, S.S. Abdool Karim, and S. Morrissey

### **Pediatrics**

Volume 148, Issue 6 December 2021

<https://pediatrics.aappublications.org/>

*Articles*

#### **Mumps in Vaccinated Children and Adolescents: 2007–2019**

Leah Shepersky, MPH; Mona Marin, MD; John Zhang, PhD; Huong Pham, MPH; Mariel A. Marlow, PhD, MPH

#### **Rotavirus Vaccine Safety and Effectiveness in Infants With High-Risk Medical Conditions**

Josephine A.P. van Dongen, MD, PhD; Elsbeth D.M. Rouers, MD; Rob Schuurman, MD; Caterina Band, MSN; Shannon M. Watkins, MSc ...

#### **The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes**

Jason M. Glanz, PhD; Christina L. Clarke, MS; Matthew F. Daley, MD; Jo Ann Shoup, PhD; Simon J. Hambidge, MD, PhD ...

### **PharmacoEconomics**

Volume 39, issue 12, December 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-12>

[New issue; No digest content identified]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>



(Accessed 4 Dec 2021)  
[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 4 Dec 2021)  
[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>  
(Accessed 4 Dec 2021)  
[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 4 Dec 2021)  
[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>  
[Accessed 4 Dec 2021]

*Research Article*

#### **Will Africans take COVID-19 vaccination?**

AbdulAzeez A. Anjorin, Ismail A. Odetokun, Ajibola I. Abioye, Hager Elnadi, Mfon Valencia Umoren, Bamu F. Damaris, Joseph Eyedo, Haruna I. Umar, Jean B. Nyandwi, Mena M. Abdalla, Sodi O. Tijani, Kwame S. Awiagah, Gbolahan A. Idowu, Sifeuh N. Achille Fabrice, Aala M. O. Maisara, Youssef Razouqi, Zuhail E. Mhgoob, Salim Parker, Osaretin E. Asowata, Ismail O. Adesanya, Maureen A. Obara, Shameem Jaumdally, Gatera F. Kitema, Taofik A. Okuneye, Kennedy M. Mbanzulu, Hajj Daitoni, Ezekiel F. Hallie, Rasha Mosbah, Folorunso O. Fasina  
Research Article | published 01 Dec 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0260575>

#### **Peer- and community-led responses to HIV: A scoping review**

George Ayala, Laurel Sprague, L. Leigh-Ann van der Merwe, Ruth Morgan Thomas, Judy Chang, Sonya Arreola, Sara L. M. Davis, Aditia Taslim, Keith Mienies, Alessandra Nilo, Lillian Mworeko, Felicita Hikuam, Carlos Garcia de Leon Moreno, José Antonio Izazola-Licea  
Research Article | published 01 Dec 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0260555>

#### **To vaccinate or not to vaccinate!? Predictors of willingness to receive Covid-19 vaccination in Europe, the U.S., and China**

Julia Brailovskaia, Silvia Schneider, Jürgen Margraf  
Research Article | published 01 Dec 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0260230>

**Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system**

George N. Ioannou, Pamela Green, Emily R. Locke, Kristin Berry

Research Article | published 01 Dec 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0259696>

**Psychological predictors of vaccination intentions among U.S. undergraduates and online panel workers during the 2020 COVID-19 pandemic**

Suryaa Gupta, Shoko Watanabe, Sean M. Laurent

Research Article | published 30 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0260380>

**COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation**

Mazin Barry, Mohamad-Hani Temsah, Abdullah Alhuzaimi, Nurah Alamro, Ayman Al-Eyadhy, Fadi Aljamaan, Basema Saddik, Ali Alhaboob, Fahad Alsohime, Khalid Alhasan, Abdulkarim Alrabiaah, Ali Alaraj, Rabih Halwani, Amr Jamal, Sarah Alsubaie, Fatimah S. Al-Shahrani, Ziad A. Memish, Jaffar A. Al-Tawfiq

Research Article | published 29 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0244415>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 4 Dec 2021]

**Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination**

Chris Davis, Nicola Logan, Grace Tyson, Richard Orton, William T. Harvey, Jonathan S. Perkins, Guy Mollett, Rachel M. Blacow, The COVID-19 Genomics UK (COG-UK) Consortium, Thomas P. Peacock, Wendy S. Barclay, Peter Cherepanov, Massimo Palmarini, Pablo R. Murcia, Arvind H. Patel, David L. Robertson, John Haughney, Emma C. Thomson, Brian J. Willett, on behalf of the COVID-19 Deployed VaccinE (DOVE) Cohort Study investigators

Research Article | published 02 Dec 2021 PLOS Pathogens

<https://doi.org/10.1371/journal.ppat.1010022>

**Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials**

Stephanie Fischinger, Deniz Cizmeci, Davy Deng, Shannon P. Grant, Nicole Frahm, Julie McElrath, Jonathan Fuchs, Pierre-Alexandre Bart, Giuseppe Pantaleo, Michael Keefer, William O. Hahn, Nadine Roupheal, Gavin Churchyard, Zoe Moodie, Yeycy Donastorg, Hendrik Streeck, Galit Alter

Research Article | published 29 Nov 2021 PLOS Pathogens

<https://doi.org/10.1371/journal.ppat.1010016>

**PNAS - Proceedings of the National Academy of Sciences of the United States**

November 23, 2021; vol. 118 no. 47

<https://www.pnas.org/content/118/47>

*Front Matter*

**Opinion: Toward inclusive global governance of human genome editing**

Hanzhi Yu, Lan Xue, Rodolphe Barrangou, Shaowei Chen, and Ying Huang

PNAS November 23, 2021 118 (47) e2118540118

<https://doi.org/10.1073/pnas.2118540118>

**Core Concept: In the wake of COVID-19, decentralized clinical trials move to center stage**

Marcus A. Banks

PNAS November 23, 2021 118 (47) e2119097118;

<https://doi.org/10.1073/pnas.2119097118>

**Prehospital & Disaster Medicine**

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 152, Part 2, November 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/152/part/P2>

***Behavior Change, Health, and Health Disparities 2021: Rural Addiction and Health***

[New issue; No digest content identified]

**Proceedings of the Royal Society B**

08 December 2021 Volume 288 Issue 1964

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

**Public Health**

Volume 200 Pages e1-e10, 1-124 (November 2021)

<https://www.sciencedirect.com/journal/public-health/vol/200/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 14, Issue 2, July 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 136 Issue 6, November/December 2021

<https://journals.sagepub.com/toc/phrg/136/6>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 31 Issue 13, November 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

## **Research Ethics**

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 4 Dec 2021]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

[No new digest content identified]

## **Risk Analysis**

Volume 41, Issue 9 Pages: 1497-1735 September 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 4 Dec 2021]

[No new digest content identified]

## **Science**

Volume 374| Issue 6572| 3 Dec 2021

<https://www.science.org/toc/science/current>

*Policy Forum*

### **Challenges in confirming drug effectiveness after early approval**

BY Holly Fernandez Lynch, Christopher T. Robertson

02 Dec 2021: 1205-1207

Reform requires clarity about whether, when, and how meaningful postapproval trials are possible

*Research Articles*

### **mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern**

BY Rishi R. Goel, et al.

03 Dec 2021

*Open Access*

Blood analysis of individuals vaccinated with the Moderna SARS-CoV-2 mRNA vaccine reveals distinct trajectories of immune memory responses.

### **Science Translational Medicine**

Volume 13| Issue 622| 1 Dec 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 289 November 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/289/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 4 Dec 2021]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 42, issue 1-2, April 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-1>

[New issue; No digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 44 November–December 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C>

*Editorial Full text access*

### **Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic**

Alfonso J. Rodríguez-Morales, D. Katterine Bonilla-Aldana, José Antonio Suárez, Carlos Franco-Paredes, ... Alberto Paniz-Mondolfi

Article 102192

*Research article Full text access*

### **Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes**

Clotilde El Guerche-Séblain, Lina Chakir, Gopinath Nageshwaran, Rebecca C. Harris, ... Philippe Vanhems

Article 102171

*Research article Open access*

**[A novel semi-quantitative methodology for national poliovirus reintroduction and outbreak risk assessment](#)**

Hendrik S. Camphor, Christina Bareja, Anna Glynn-Robinson, Benjamin G. Polkinghorne, David N. Durrheim

Article 102181

**Tropical Medicine & International Health**

Volume 26, Issue 12 Pages: i-iv, 1527-1717 December 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

**Vaccine**

Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48>

*Discussion Full text access*

**[Multicomponent vaccines to fight SARS-CoV-2 variants of concern](#)**

Antonio Cassone, Roberto Cauda

Pages 6969-6971

*Discussion Full text access*

**[Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future](#)**

Divya Hosangadi, Elena K. Martin, Matthew Watson, Richard Bruns, Nancy Connell

Pages 6972-6974

*Short communication Full text access*

**[COVID-19 vaccine – Long term immune decline and breakthrough infections](#)**

Johad Khoury, Ronza Najjar-Debbiny, Ayman Hanna, Adel Jabbour, ... Fahed Hakim

Pages 6984-6989

*Research article Abstract only*

**[Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020](#)**

Sara Sanz-Rojo, Rodrigo Jiménez-García, Ana López-de-Andrés, Javier de Miguel-Diez, ... José J. Zamorano-León

Pages 7012-7020

*Research article Full text access*

**[COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study](#)**

Helena C. Maltezou, Periklis Panagopoulos, Flora Sourri, Theodoros V. Giannouchos, ... Dimitrios Hatzigeorgiou

Pages 7021-7027

*Research article Full text access*

**Changes in COVID-19 vaccine acceptance rate among recovered critically ill patients: A 12-month follow-up study**

Titilope Olanipekun, Temidayo Abe, Valery Effoe, Gloria Westney, Richard Snyder  
Pages 7074-7081

*Research article Open access*

**Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study**

Maria Esterlita T. Villanueva-Uy, Hilton Y. Lam, Josephine G. Aldaba, Tristan Marvin Z. Uy, ... Clint Pecenka  
Pages 7091-7100

*Research article Open access*

**Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)**

Thomas Byrne, Parth Patel, Madhumita Shrotri, Sarah Beale, ... Richard Gilson  
Pages 7108-7116

**Value in Health**

December 2021 Volume 24 Issue 12 p1715-1870

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

.....

.....

**Pre-Print Servers**

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 4 Dec 2021]

*No new digest content identified.*

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

*medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...*

[Accessed 4 Dec 2021]

*Selected Content*

**Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).**

Francisco Hernandez-Bernal, Maria del Carmen Ricardo-Cobas, Yenima Martin-Bauta, Zadis Navarro-Rodriguez, Marjoris Pinera-Martinez, Joel Quintana-Guerra, Karen Urrutia-Perez, Klaudia Urrutia-Perez, Cristina Olimpia Chavez-Chong, Jorge Luis Azor-Hernandez, Jose Luis Rodriguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Avila, Jacqueline Bizet-Almeida, Jeniffer Rodriguez-Nuviola, Sergio del Valle-Pinera, Mayara Ramirez-Dominguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdes, Gilda Lemos-Perez, Gerardo Enrique Guillen-Nieto, Ariel Palenzuela-Diaz, Enrique Noa-Romero, Miladys Limonta-Fernandez, Juan Manuel Fernandez-Avila, Nabil Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Avila, Verena Lucila Muzio-Gonzalez  
medRxiv 2021.11.30.21267047; doi: <https://doi.org/10.1101/2021.11.30.21267047> Revision

### **Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders**

Douglas Lake, Alexa J Roeder, Maria J Gonzalez-Moa, Megan Koehler, Erin Kaleta, Paniz Jasbi, John Vanderhoof, Davis Mckechnie, Jack Forman, Baylee Edwards, Alim Seit-Nebi, Sergei Svarovsky  
medRxiv 2021.11.30.21266716; doi: <https://doi.org/10.1101/2021.11.30.21266716>

### **The Politics of Vaccine Hesitancy in the United States**

Jian Cao, Christina Ramirez, R. Michael Alvarez  
medRxiv 2021.12.01.21267160; doi: <https://doi.org/10.1101/2021.12.01.21267160>

### **Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: a modeling study.**

Clement R Massonnaud, Jonathan Roux, Vittoria Colizza, Pascal Crepey  
medRxiv 2021.12.01.21267122; doi: <https://doi.org/10.1101/2021.12.01.21267122>

### **Changes Over Time in COVID-19 Vaccination Inequalities in Eight Large U.S. Cities**

S. Michael Gaddis, Colleen M. Carey, Nicholas V DiRago  
medRxiv 2021.12.01.21267158; doi: <https://doi.org/10.1101/2021.12.01.21267158>

### **Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications**

Andrew T Levin, Nana Owusu-Boaitey, Sierra Pugh, Bailey K Fosdick, Anthony B. Zwi, Anup Malani, Satej Soman, Lonni Besançon, Ilya Kashnitsky, Sachin Ganesh, Aloysius McLaughlin, Gayeong Song, Rine Uhm, Gideon Meyerowitz-Katz  
medRxiv 2021.09.29.21264325; doi: <https://doi.org/10.1101/2021.09.29.21264325>

### **Convalescent plasma for outpatients with early COVID-19**

Pere Millat-Martinez, Arvind Gharbharan, Andrea Alemany, Casper Rokx, Corine GeurtsvanKessel, Grigorios Papageorgiou, Nan van Geloven, Carlijn Jordans, Geert Groeneveld, Francis Swaneveld, Ellen van der Schoot, Marc Corbacho-Monne, Dan Ouchi, Francini Piccolo Ferreira, Pierre Malchair, Sebastian Videla, Vanesa Garcia Garcia, Anna Ruiz-Comellas, Anna Ramirez-Morros, Joana Rodriguez Codina, Rosa Amado Simon, Joan-Ramon Grifols, Julia Blanco, Ignacio Blanco, Jordi Ara, Quique Bassat, Bonaventura Clotet, Barbara Baro, Andrea Troxel, Jaap Jan Zwaginga, Oriol Mitja, Bart Rijnders  
medRxiv 2021.11.30.21266810; doi: <https://doi.org/10.1101/2021.11.30.21266810>

### **Google Trends as a predictive tool for COVID-19 vaccinations in Italy: a retrospective infodemiological analysis**

Alessandro Rovetta  
medRxiv 2021.11.29.21267012; doi: <https://doi.org/10.1101/2021.11.29.21267012>



**The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series**

Nasikarn Angkasekwinai, Suvimol Niyomnaitham, Jaturong Sewatanon, Supaporn Phumiamorn, Kasama Sukapirom, Sansnee Senawong, Surakameth Mahasirimongkol, Zheng Quan Toh, Pinklow Umrod, Thitiporn Somporn, Supaporn Chumpol, Kanokphon Ritthitham, Kulkanya Chokephaibulkit  
medRxiv 2021.11.29.21266947; doi: <https://doi.org/10.1101/2021.11.29.21266947>

**Critical success factors for routine immunization performance: A case study of Zambia 2000 to 2018**

Katie Rodriguez, Kyra A. Hester, Chama Chanda, Roopa Darwar, Bonheur Dounebaine, Anna S. Ellis, Pinar Keskinocak, Abimbola Leslie, Mwangala Manyando, Maurice Sililo Manyando, Dima Nazzal, Emily Awino Ogutu, Zoe Sakas, Francisco Castillo-Zunino, William Kilembe, Robert A. Bednarczyk, Matthew C. Freeman, the Vaccine Exemplars Research Consortium  
medRxiv 2021.11.30.21267060; doi: <https://doi.org/10.1101/2021.11.30.21267060>

**Use of Artificial Intelligence on spatio-temporal data to generate insights during COVID-19 pandemic: A Review**

Gihan Jayatilaka, Jameel Hassan, Umar Marikkar, Rumali Perera, Suren Sritharan, Harshana Weligampola, Mevan Ekanayake, Roshan Godaliyadda, Parakrama Ekanayake, Vijitha Herath, G M Dilshan Godaliyadda, Anuruddhika Rathnayake, Samath D. Dharmaratne, Janaka Ekanayake  
medRxiv 2020.11.22.20232959; doi: <https://doi.org/10.1101/2020.11.22.20232959>

**Wellcome Open Research** [to 4 Dec 2021]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 4 Dec 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

*Research Article metrics* Revised

**10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity** [version 2; peer review: 2 approved with reservations]

John W.G. Addy, Yaw Bediako, Francis M. Ndungu, John Joseph Valetta, Adam J. Reid, Jedida Mwacharo, Joyce Mwongeli Ngoi, Joshua Wambua, Edward Otieno, Jennifer Musyoki, Khadija Said, Matthew Berriman, Kevin Marsh, Philip Bejon, Mario Recker, Jean Langhorne  
Peer Reviewers Rodrigo M Corder; Rhea J Longley  
Funders: Wellcome Trust; Francis Crick Institute; Medical Research Council  
LATEST VERSION PUBLISHED 03 Dec 2021

*Data Note metrics* Revised

**The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Home-based antibody testing results, October 2020. An emphasis on self-screening at a population level** [version 2; peer review: 1 approved, 2 approved with reservations]

Kate Northstone, Daniel Smith, Claire Bowring, Amanda Hill, Richard Hobbs, Nicholas Wells, Nicholas J. Timpson

Peer Reviewers Morteza Taheri; Jean-Luc Murk; Citra N.Z. Mattar  
Funders: Wellcome Trust; Medical Research Council  
LATEST VERSION PUBLISHED 02 Dec 2021

*Open Letter metrics Revised*

**[An ethical analysis of vaccinating children against COVID-19: benefits, risks, and issues of global health equity](#)** [version 2; peer review: 1 approved, 1 approved with reservations]

Rachel Gur-Arie, Steven R. Kraaijeveld, Euzebiusz Jamrozik

Peer Reviewers Stefan David Baral; Tracy Beth Høeg

Funders: Wellcome Trust; ZonMw

LATEST VERSION PUBLISHED 29 Nov 2021

*Abstract*

COVID-19 vaccination of children has begun in various high-income countries with regulatory approval and general public support, but largely without careful ethical consideration. This trend is expected to extend to other COVID-19 vaccines and lower ages as clinical trials progress. This paper provides an ethical analysis of COVID-19 vaccination of healthy children. Specifically, we argue that it is currently unclear whether routine COVID-19 vaccination of healthy children is ethically justified in most contexts, given the minimal direct benefit that COVID-19 vaccination provides to children, the potential for rare risks to outweigh these benefits and undermine vaccine confidence, and substantial evidence that COVID-19 vaccination confers adequate protection to risk groups, such as older adults, without the need to vaccinate healthy children. We conclude that child COVID-19 vaccination in wealthy communities before adults in poor communities worldwide is ethically unacceptable and consider how policy deliberations might evolve in light of future developments.

\* \* \* \*

## **Think Tanks**

**Brookings** [to 4 Dec 2021]

<http://www.brookings.edu/>

Accessed 4 Dec 2021

*Africa in Focus*

**[What do Pfizer's 1996 drug trials in Nigeria teach us about vaccine hesitancy?](#)**

Belinda Archibong and Francis Annan

Friday, December 3, 2021

*Report*

**[We are not guinea pigs: The effects of negative news on vaccine compliance](#)**

Belinda Archibong and Francis Annan

Friday, December 3, 2021

**Center for Global Development** [to 4 Dec 2021]

<http://www.cgdev.org/page/press-center>

Accessed 4 Dec 2021

**[Africa Should Bargain Hard for COVID Vaccine Equity: Lessons from Indonesia during Avian Flu](#)**

December 2, 2021

Many countries around the world have punished most of the African continent for the scientific discovery of the Omicron variant through the imposition of travel bans. These travel bans are more injury upon the injury of low vaccination in Africa. Even well-intentioned rallying phrases such as “vaccine apartheid” or “vaccine equity” still lack the moral weight, indignation, and urgency that we should all feel, no matter which country we live. Words fail us.

Victoria Fan and Steve Kuo

### **Development Agencies and the “New Normal”**

December 1, 2021

In this blog, we map key trends and changes in the development landscape and highlight the implications of these changes for the future of ODA. These findings were presented at the Development Leaders Conference 2021, held earlier this month. All development agencies will need to ask themselves how to better address challenges that extend beyond national boundaries and how to respond to the increasing incidence of poverty and inequality at the national level. Both approaches are linked and can co-exist. But they require a re-think of roles, practices and capacities

Rachael Calleja and Mikaela Gavas

### **MDB COVID-19 Crisis Response: Where Did the Money Go?**

*Publication*

November 30, 2021

The pandemic and its economic impact have been a revealing test of the multilateral development bank (MDB) system and of individual MDBs. Although lending by the MDBs as a group rose significantly in 2020 (39 percent), this is much less than the rise in MDB lending in response to the Global Financial Crisis (77 percent), despite the much greater economic and social costs of the pandemic.

### **African Countries Will Continue to Face Tough Choices on COVID-19 Vaccines: We’ve Developed a Toolkit That Can Help**

November 29, 2021

*African countries will continue to face tough choices on COVID-19 vaccines—we’ve developed a Toolkit that can help.*

Tom Drake, Justice Nonvignon and Y-Ling Chi

**Chatham House** [to 4 Dec 2021]

<https://www.chathamhouse.org/>

*Accessed 4 Dec 2021*

### **COVID-19: What is needed to address emergent pathogens?**

Omicron highlights why a global regime is needed to support countries reporting variants, and that a shared sense of well-being has to come to the fore.

*Expert comment*

1 December 2021

Dr Osman Dar

Project Director, One Health Project, Global Health Programme

**CSIS**

<https://www.csis.org/>

*Accessed 4 Dec 2021*

*Podcast Episode*

### **Seth Berkley on COVAX's Past, Present and Future**

December 1, 2021 | By [Katherine E. Bliss](#)

In this episode, an edited version of a live event on November 15, Katherine talks with Seth Berkley, CEO of Gavi, the Vaccine Alliance, about the first year and a half of COVAX, the global collaboration focused on ensuring globally equitable access to Covid-19 vaccines. One year after the first vaccines were made available, their distribution remains highly unequal, with an overwhelming majority of doses so far delivered to populations in high-income countries. Even as vaccine production has expanded, inequities have worsened, especially among lower-income countries. What difficult lessons have been learned over COVAX's first year and a half? How likely is it that populations in lower-income countries will have access to Covid-19 vaccines in 2022? And how can countries that have surplus vaccines best support COVAX and the distribution of vaccines globally?

*Podcast Episode*

### **Dr. Richard Lessells: Omicron Seen Up Close in South Africa**

December 1, 2021 | By [J. Stephen Morrison](#), [H. Andrew Schwartz](#)

Dr. Richard Lessells is among the exceptional South African experts on the front lines of discovering and investigating Omicron in South Africa. Alarm bells went off within the scientific community, as it became clear after just a few days that "an extraordinary number of mutations" are clustered in the key regions in the genome for immune protection and transmissibility. It was a "gut feeling. "...

### **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 4 Dec 2021*

December 2, 2021 *News Release*

### **Nearly a Quarter of Vaccinated Adults Received a COVID-19 Booster Shot, Up Sharply from October; Most Other Vaccinated Adults Expect to Get a Booster, Though About 1 in 5 Say They Likely Won't**

*Public is Less Optimistic and More Frustrated with State of Vaccinations Now Than in January*

Nearly a quarter (23%) of fully vaccinated adults have already received a COVID-19 booster shot, more than double the share who had done so in October (10%), the latest KFF COVID-19 Vaccine Monitor report reveals....

### **ODI [Overseas Development Institute] [to 4 Dec 2021]**

<https://odi.org/en/publications/>

*Publications*

[No new digest content identified]

\*

\*

\*

\*

### **Contents [click to move among sections]**

:: [\*Milestones - Perspectives\*](#)

:: [\*Coronavirus \[COVID-19\] - WHO\*](#)

:: [\*Emergencies\*](#)

:: [\*Organization Announcements\*](#)

:: Journal Watch

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*